{"ctNumber":"2026-526741-10-00","ctStatus":"Authorised","decisionDate":"2026-10-30T13:47:47.556","publishDate":"2026-11-05T02:35:39.178904269","ctPublicStatusCode":2,"authorizedApplication":{"authorizedPartI":{"id":147374,"rowSubjectCount":83,"rowCountriesInfo":[{"eutctId":100000000439,"name":"Korea, Republic of","isoNumber":410,"isoAlpha2Code":"KR","isoAlpha3Code":"KOR","current":true},{"eutctId":100000000556,"name":"United Kingdom","isoNumber":826,"isoAlpha2Code":"GB","isoAlpha3Code":"GBR","current":true},{"eutctId":100000000541,"name":"Thailand","isoNumber":764,"isoAlpha2Code":"TH","isoAlpha3Code":"THA","current":true},{"eutctId":100000000538,"name":"Taiwan","isoNumber":158,"isoAlpha2Code":"TW","isoAlpha3Code":"TWN","current":true},{"eutctId":100000000456,"name":"Malaysia","isoNumber":458,"isoAlpha2Code":"MY","isoAlpha3Code":"MYS","current":true},{"eutctId":100000000557,"name":"United States","isoNumber":840,"isoAlpha2Code":"US","isoAlpha3Code":"USA","current":true},{"eutctId":100000000329,"name":"Australia","isoNumber":36,"isoAlpha2Code":"AU","isoAlpha3Code":"AUS","current":true}],"products":[{"id":616425,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12980657","productPharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12980657","prodAuthStatus":1,"prodName":"Ficerafusp Alfa","pharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","sponsorProductCode":"BCA101","activeSubstanceName":"FICERAFUSP ALFA","euSubstNumber":"SUB301432","nameOrg":"BICARA","productSubstances":[{"productPk":"12980657","substancePk":"404854","nameOrg":"BICARA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"FICERAFUSP ALFA","substanceEvCode":"SUB301432","synonyms":["Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta","BCA101","Ficerafusp alpha"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2250","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"195.75","maxTreatmentPeriod":60,"timeUnitCode":"3","otherMedicinalProduct":"chimeric EGFR mAb & TGF-β TGF-βRIIECD","evCode":"PRD12980657","sponsorProductCodeEdit":"BCA101","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"Ficerafusp Alfa","jsonActiveSubstanceNames":"ficerafusp alfa","pharmaceuticalFormDisplay":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION"},{"id":616426,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"14197451","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081132","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"14197451","substancePk":"450549","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136","synonyms":["Lambrolizumab","MK-3475","SCH-900475","BAT3306","Pabolizumab","FYB206","CT P51","SYS6036","QL-2107","CMAB820","ABP 234"]}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"7","productChangedRelationMA":false,"maxTreatmentPeriod":24,"timeUnitCode":"3","otherMedicinalProduct":"humanised monoclonal anti-programmed cell death-1 (PD-1) antibody","evCode":"PRD12081132","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Multicenter, open-label, randomized Phase 2 study evaluating continuous weekly dosing of ficerafusp alfa (BCA101) in combination with pembrolizumab versus an alternative dosing regimen for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma","fullTitleTranslations":[{"id":12576831,"uuid":"025f1b7c-da24-4077-90f5-dfb6b5837d42","attributeTranslation":"Estudio de fase II, multicéntrico, en abierto y aleatorizado para evaluar la administración semanal continua de ficerafusp alfa (BCA101) en combinación con pembrolizumab, frente a una pauta posológica alternativa de ficerafusp alfa, para el tratamiento de primera línea del carcinoma epidermoide de cabeza y cuello recurrente o metastásico","language":7,"languageDescription":"Spanish"},{"id":12576832,"uuid":"025f1b7c-da24-4077-90f5-dfb6b5837d42","attributeTranslation":"Wieloośrodkowe, prowadzone metodą otwartej próby, randomizowane badanie fazy 2 oceniające ciągłe cotygodniowe podawanie ficerafuspu alfa (BCA101) w skojarzeniu z pembrolizumabem w porównaniu z alternatywnym schematem dawkowania ficerafuspu alfa w leczeniu pierwszego rzutu u pacjentów z nawrotowym lub przerzutowym rakiem płaskonabłonkowym głowy i szyi","language":19,"languageDescription":"Polish"},{"id":12576834,"uuid":"025f1b7c-da24-4077-90f5-dfb6b5837d42","attributeTranslation":"Een multicenter, open-label, gerandomiseerd fase 2-onderzoek ter beoordeling van een doorlopende wekelijkse toediening van ficerafusp alfa (BCA101) in combinatie met pembrolizumab versus een alternatief toedieningsschema van ficerafusp alfa voor de eerstelijnsbehandeling van recidiverend of gemetastaseerd plaveiselcelcarcinoom van het hoofd-halsgebied","language":18,"languageDescription":"Dutch"},{"id":12576833,"uuid":"025f1b7c-da24-4077-90f5-dfb6b5837d42","attributeTranslation":"Étude de phase II multicentrique, en ouvert, randomisée, visant à évaluer l’administration hebdomadaire continue du ficerafusp alfa (BCA101) en association avec le pembrolizumab par rapport à un autre schéma posologique du ficerafusp alfa dans le traitement de première ligne du carcinome épidermoïde de la tête et du cou récidivant ou métastatique","language":34,"languageDescription":"French (France)"}],"publicTitle":"A Phase 2 Randomized Open-label Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination with Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC","publicTitleTranslations":[{"id":12576891,"uuid":"c9dcd28c-4615-4e40-b7dc-a2f43dcd4728","attributeTranslation":"Randomizowane, prowadzone metodą otwartej próby badanie fazy 2 oceniające ficerafusp alfa (BCA101) podawany raz na tydzień w skojarzeniu z pembrolizumabem w porównaniu z alternatywnym schematem dawkowania ficerafuspu alfa w leczeniu pierwszego rzutu w nawrotowym lub przerzutowym raku płaskonabłonkowym głowy i szyi","language":19,"languageDescription":"Polish"},{"id":12576893,"uuid":"c9dcd28c-4615-4e40-b7dc-a2f43dcd4728","attributeTranslation":"Een gerandomiseerd, open label fase 2-onderzoek ter beoordeling van ficerafusp alfa (BCA101) eenmaal per week in combinatie met pembrolizumab vergeleken met een alternatieve toediening van ficerafusp alfa bij eerstelijnsbehandeling van recidiverend of gemetastaseerd plaveiselcelcarcinoom van het hoofd-halsgebied","language":18,"languageDescription":"Dutch"},{"id":12576892,"uuid":"c9dcd28c-4615-4e40-b7dc-a2f43dcd4728","attributeTranslation":"Estudio de fase II en abierto y aleatorizado para evaluar ficerafusp alfa (BCA101) una vez por semana en combinación con pembrolizumab frente a otra pauta posológica de ficerafusp alfa de primera línea para el CECC R o M","language":7,"languageDescription":"Spanish"},{"id":12576894,"uuid":"c9dcd28c-4615-4e40-b7dc-a2f43dcd4728","attributeTranslation":"Étude de phase II, en ouvert, randomisée, évaluant le ficerafusp alfa (BCA101) administré 1x/semaine en association avec le pembrolizumab par rapport à un autre schéma posologique du ficerafusp alfa dans le traitement de 1re ligne du CETC R ou M","language":34,"languageDescription":"French (France)"}],"shortTitle":"BCA101X201","secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"BCA101X201 is a Phase 2 which in line with EMA guidance on disclosure rules corresponds to a Category 2 trial.","trialCategoryId":136602},"medicalCondition":{"partIMedicalConditions":[{"id":154733,"medicalCondition":"Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","medicalConditionTranslations":[{"id":12576705,"uuid":"3ca9c36f-0622-4a9f-ac1a-95f773007378","attributeTranslation":"Recidiverend of gemetastaseerd plaveiselcelcarcinoom van het hoofd-halsgebied","language":18,"languageDescription":"Dutch"},{"id":12576706,"uuid":"3ca9c36f-0622-4a9f-ac1a-95f773007378","attributeTranslation":"Carcinoma epidermoide de cabeza y cuello recurrente o metastásico","language":7,"languageDescription":"Spanish"},{"id":12576704,"uuid":"3ca9c36f-0622-4a9f-ac1a-95f773007378","attributeTranslation":"Carcinome épidermoïde de la tête et du cou récidivant ou métastatique","language":34,"languageDescription":"French (France)"},{"id":12576703,"uuid":"3ca9c36f-0622-4a9f-ac1a-95f773007378","attributeTranslation":"Nawrotowy lub przerzutowy rak płaskonabłonkowy głowy i szyi","language":19,"languageDescription":"Polish"}],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":200000042781,"version":"27.0","level":"LLT","termName":"Squamous cell carcinoma of head and neck recurrent","classificationCode":"10090001","organClass":100000004864,"active":false},{"termId":200000009936,"version":"27.0","level":"LLT","termName":"Squamous cell carcinoma of head and neck metastatic","classificationCode":"10082179","organClass":10029104,"active":false}]},"trialObjective":{"trialScopes":[{"code":"6","trialScopeId":449044},{"code":"5","trialScopeId":449047},{"code":"7","trialScopeId":449048},{"code":"13","otherDescription":"Tolerability","trialScopeId":449046},{"code":"4","trialScopeId":449049},{"code":"3","trialScopeId":449045}],"mainObjective":"To evaluate whether the antitumor activity of the once every 3 weeks (Q3W) alternative ficerafusp alfa dosing regimen is maintained when compared to the standard weekly dosing regimen after randomization","mainObjectiveTranslations":[{"id":12576889,"uuid":"d6681c61-6131-4b99-a73f-882681520f0b","attributeTranslation":"Een gerandomiseerd, open label fase 2-onderzoek ter beoordeling van ficerafusp alfa (BCA101) eenmaal per week in combinatie met pembrolizumab vergeleken met een alternatieve toediening van ficerafusp alfa bij eerstelijnsbehandeling van recidiverend of gemetastaseerd plaveiselcelcarcinoom van het hoofd-halsgebied","language":18,"languageDescription":"Dutch"},{"id":12576887,"uuid":"d6681c61-6131-4b99-a73f-882681520f0b","attributeTranslation":"Evaluar si la actividad antitumoral de la pauta posológica alternativa de ficerafusp alfa cada tres semanas (c3sem) se mantiene en comparación con la pauta posológica semanal habitual tras la aleatorización","language":7,"languageDescription":"Spanish"},{"id":12576890,"uuid":"d6681c61-6131-4b99-a73f-882681520f0b","attributeTranslation":"Ocena, czy aktywność przeciwnowotworowa alternatywnego schematu podawania ficerafuspu alfa raz na 3 tygodnie (Q3W) jest utrzymana w porównaniu ze standardowym schematem podawania co tydzień po randomizacji","language":19,"languageDescription":"Polish"},{"id":12576888,"uuid":"d6681c61-6131-4b99-a73f-882681520f0b","attributeTranslation":"Évaluer si l’activité antitumorale du schéma posologique alternatif du ficerafusp alfa administré toutes les 3 semaines (1x/3 sem) est maintenue par rapport au schéma posologique hebdomadaire standard après la randomisation.","language":34,"languageDescription":"French (France)"}],"secondaryObjectives":[{"id":530128,"number":1,"secondaryObjective":"1. To evaluate the pharmacokinetics of  ficerafusp alfa","secondaryObjectiveTranslations":[{"id":12576895,"uuid":"20b1ed13-fc15-47cb-8774-91e5a49b90f2","attributeTranslation":"1. Évaluer la pharmacocinétique du ficerafusp alfa.","language":34,"languageDescription":"French (France)"},{"id":12576897,"uuid":"20b1ed13-fc15-47cb-8774-91e5a49b90f2","attributeTranslation":"1. Evaluar las propiedades farmacocinéticas de ficerafusp alfa","language":7,"languageDescription":"Spanish"},{"id":12576896,"uuid":"20b1ed13-fc15-47cb-8774-91e5a49b90f2","attributeTranslation":"1. Het beoordelen van de farmacokinetiek van ficerafusp alfa","language":18,"languageDescription":"Dutch"},{"id":12576898,"uuid":"20b1ed13-fc15-47cb-8774-91e5a49b90f2","attributeTranslation":"1. Ocena farmakokinetyki ficerafuspu alfa","language":19,"languageDescription":"Polish"}]},{"id":530129,"number":2,"secondaryObjective":"2. To further evaluate antitumor activity during the maintenance phase for participants receiving the alternative and standard dosing regimens","secondaryObjectiveTranslations":[{"id":12576902,"uuid":"9a81aa6b-f608-45a5-aba2-a3c6fc8003d3","attributeTranslation":"2. Dalsza ocena aktywności przeciwnowotworowej w fazie leczenia podtrzymującego u uczestników otrzymujących\nleczenie według alternatywnego i standardowego schematu podawania","language":19,"languageDescription":"Polish"},{"id":12576901,"uuid":"9a81aa6b-f608-45a5-aba2-a3c6fc8003d3","attributeTranslation":"2. Évaluer plus avant l’activité antitumorale pendant la phase d’entretien chez les participants recevant les schémas posologiques alternatif et standard.","language":34,"languageDescription":"French (France)"},{"id":12576900,"uuid":"9a81aa6b-f608-45a5-aba2-a3c6fc8003d3","attributeTranslation":"2. Het verder beoordelen van de antitumoractiviteit tijdens de onderhoudsfase bij deelnemers die het alternatieve en het standaard toedieningsschema volgen","language":18,"languageDescription":"Dutch"},{"id":12576899,"uuid":"9a81aa6b-f608-45a5-aba2-a3c6fc8003d3","attributeTranslation":"2. Evaluar en mayor profundidad la actividad antitumoral durante la fase de mantenimiento en los participantes que reciben las pautas posológicas alternativa y habitual","language":7,"languageDescription":"Spanish"}]},{"id":530130,"number":3,"secondaryObjective":"3. To evaluate antitumor activity for the  overall dosing regimen across the full study treatment course, including both loading and maintenance phases","secondaryObjectiveTranslations":[{"id":12576904,"uuid":"33282423-6afb-4759-ad4c-e630821d734a","attributeTranslation":"3. Het beoordelen van de antitumoractiviteit voor het totale toedieningsschema gedurende de gehele behandelperiode van het onderzoek, met inbegrip van zowel de oplaad- als de onderhoudsfase","language":18,"languageDescription":"Dutch"},{"id":12576903,"uuid":"33282423-6afb-4759-ad4c-e630821d734a","attributeTranslation":"3. Evaluar la actividad antitumoral de la pauta posológica global a lo largo de todo el ciclo de tratamiento del estudio, incluidas la fase de carga y la de mantenimiento","language":7,"languageDescription":"Spanish"},{"id":12576905,"uuid":"33282423-6afb-4759-ad4c-e630821d734a","attributeTranslation":"3. Ocena aktywności przeciwnowotworowej wszystkich schematów podawania w całym okresie badanego leczenia, w tym zarówno w fazie nasycającej, jak i w fazie leczenia podtrzymującego","language":19,"languageDescription":"Polish"},{"id":12576906,"uuid":"33282423-6afb-4759-ad4c-e630821d734a","attributeTranslation":"3. Évaluer l’activité antitumorale pour le schéma posologique global sur toute la durée du traitement à l’étude, y compris les phases de charge et d’entretien.","language":34,"languageDescription":"French (France)"}]},{"id":530131,"number":4,"secondaryObjective":"4. To evaluate the safety and tolerability profile during the maintenance phase for participants receiving the alternative and standard maintenance dosing regimens","secondaryObjectiveTranslations":[{"id":12576909,"uuid":"633c9ce4-f5a2-416c-8989-20a89d005b58","attributeTranslation":"4. Ocena profilu bezpieczeństwa stosowania i tolerancji w fazie leczenia podtrzymującego u uczestników otrzymujących leczenie podtrzymujące według alternatywnego i standardowego schematu podawania","language":19,"languageDescription":"Polish"},{"id":12576907,"uuid":"633c9ce4-f5a2-416c-8989-20a89d005b58","attributeTranslation":"4. Het verder beoordelen van het veiligheids- en verdraagbaarheidsprofiel tijdens de onderhoudsfase bij deelnemers die het alternatieve en het standaard toedieningsschema volgen","language":18,"languageDescription":"Dutch"},{"id":12576910,"uuid":"633c9ce4-f5a2-416c-8989-20a89d005b58","attributeTranslation":"4. Evaluar el perfil de seguridad y tolerabilidad durante la fase de mantenimiento en los participantes que reciben las pautas posológicas de mantenimiento alternativa y habitual","language":7,"languageDescription":"Spanish"},{"id":12576908,"uuid":"633c9ce4-f5a2-416c-8989-20a89d005b58","attributeTranslation":"4. Évaluer le profil de sécurité d’emploi et de tolérance pendant la phase d’entretien chez les participants recevant les schémas posologiques d’entretien alternatif et standard.","language":34,"languageDescription":"French (France)"}]},{"id":530132,"number":5,"secondaryObjective":"5. To evaluate the safety and tolerability profile for the overall dosing regimen across the full study treatment course, including both loading and maintenance phase","secondaryObjectiveTranslations":[{"id":12576914,"uuid":"7398b4d9-0ffe-4b04-8747-2226210da0b0","attributeTranslation":"5. Het beoordelen van het veiligheids- en verdraagbaarheidsprofiel voor het totale toedieningsschema gedurende de gehele behandelperiode van het onderzoek, met inbegrip van zowel de oplaad- als de onderhoudsfase","language":18,"languageDescription":"Dutch"},{"id":12576912,"uuid":"7398b4d9-0ffe-4b04-8747-2226210da0b0","attributeTranslation":"5. Ocena profilu bezpieczeństwa stosowania i tolerancji wszystkich schematów dawkowania w całym okresie badanego leczenia, w tym zarówno w fazie nasycającej, jak i w fazie leczenia podtrzymującego","language":19,"languageDescription":"Polish"},{"id":12576913,"uuid":"7398b4d9-0ffe-4b04-8747-2226210da0b0","attributeTranslation":"5. Évaluer le profil de sécurité d’emploi et de tolérance du schéma posologique global sur toute la durée du traitement à l’étude, y compris les phases de charge et d’entretien.","language":34,"languageDescription":"French (France)"},{"id":12576911,"uuid":"7398b4d9-0ffe-4b04-8747-2226210da0b0","attributeTranslation":"5. Evaluar la el perfil de seguridad y tolerabilidad de la pauta posológica global a lo largo de todo el ciclo de tratamiento del estudio, incluidas la fase de carga y la de mantenimiento","language":7,"languageDescription":"Spanish"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":1006710,"number":1,"principalInclusionCriteria":"1. Participant or legally authorized representative, if applicable, has signed and dated informed consent form (ICF) indicating that the participant (or legally authorized representative, if applicable) has been informed of all the pertinent aspects of the study prior to enrollment and the participant must be willing to comply with all study procedures for the duration of the study. For participants at sites in the EU and UK: A legally authorized representative may not provide consent on behalf of a participant. Only participants with decision-making capacity/participants that are legally competent can be included in the study.","principalInclusionCriteriaTranslations":[{"id":12576835,"uuid":"2e0937c5-553d-4a46-8c06-050b38a7707a","attributeTranslation":"1. Le/la participant(e) ou son/sa représentant(e) légal(e), le cas échéant, a daté et signé le formulaire de consentement éclairé (FCE), attestant qu’il/elle a été informé(e) de tous les aspects pertinents de l’étude avant son inclusion et qu’il/elle accepte de se conformer à toutes les procédures de l’étude pendant toute sa durée.\nPour les participants des centres situés dans l’UE ou au Royaume-Uni : aucun(e) représentant(e) légal(e) ne peut donner son consentement au nom d’un(e) participant(e). Seuls les participants capables de prendre une décision et juridiquement aptes à consentir peuvent être inclus dans l’étude.","language":34,"languageDescription":"French (France)"},{"id":12576838,"uuid":"2e0937c5-553d-4a46-8c06-050b38a7707a","attributeTranslation":"1. Uczestnik lub jego przedstawiciel ustawowy, w stosownych przypadkach, podpisał i opatrzył datą formularz świadomej zgody (ICF), w celu potwierdzenia, że uczestnik (lub jego przedstawiciel ustawowy, w stosownych przypadkach) został poinformowany o wszystkich istotnych aspektach badania przed włączeniem go do badania oraz że uczestnik powinien wyrazić gotowość do przestrzegania wszystkich procedur badania przez cały czas trwania badania.\nW przypadku uczestników w ośrodkach na terenie UE i Wielkiej Brytanii: przedstawiciel ustawowy nie może wyrazić zgody w imieniu uczestnika. Do badania mogą zostać włączeni wyłącznie uczestnicy posiadający zdolność do podejmowania decyzji/posiadający pełną zdolność do czynności prawnych.","language":19,"languageDescription":"Polish"},{"id":12576836,"uuid":"2e0937c5-553d-4a46-8c06-050b38a7707a","attributeTranslation":"1. El participante o su representante legal, si procede, ha firmado y fechado el documento de consentimiento informado (DCI) en el que se indica que se ha informado al participante (o a su representante legal, si procede) de todos los aspectos pertinentes del estudio antes de su inclusión, y que el participante debe estar dispuesto a cumplir con todos los procedimientos del estudio durante todo el estudio.\nPara participantes en centros de la UE y RU: Un representante legal no podrá proporcionar el consentimiento en nombre de un participante. Solo se podrá incluir en el estudio a participantes con capacidad para tomar decisiones o capacidad de obrar.","language":7,"languageDescription":"Spanish"},{"id":12576837,"uuid":"2e0937c5-553d-4a46-8c06-050b38a7707a","attributeTranslation":"1. De deelnemer of, indien van toepassing, de wettelijk bevoegde vertegenwoordiger heeft het patiënteninformatie- en toestemmingsformulier (PIF) ondertekend en gedateerd, waaruit blijkt dat de deelnemer (of, indien van toepassing, de wettelijk bevoegde vertegenwoordiger) vóór de inschrijving op de hoogte is gesteld van alle relevante aspecten van het onderzoek en de deelnemer moet bereid zijn om zich gedurende de gehele looptijd van het onderzoek aan alle onderzoeksprocedures te houden\nVoor deelnemers op centra in de EU en het VK: Een wettelijk bevoegde vertegenwoordiger mag geen toestemming geven namens een deelnemer. Alleen deelnemers met beslissingsbevoegdheid/deelnemers die wettelijk bekwaam zijn, kunnen in het onderzoek worden ingeschreven.","language":18,"languageDescription":"Dutch"}]},{"id":1006711,"number":10,"principalInclusionCriteria":"10. Participant demonstrates adequate organ function, defined as follows: Hematological :Absolute neutrophil count (ANC) ≥1500/μL (1.5×10^9/L); Platelets ≥100,000/μL (100×10^9/L); Hemoglobin ≥9 g/dL (90 g/L) or ≥5.6 mmol/L. Must be met without packed red blood cell transfusion in the prior 7 days. Renal: Creatinine clearance (CrCl) measured or calculated per institutional standards (CrCl or estimated glomerular filtration rate mL/min). Hepatic: Total serum bilirubin ≤1.5× upper limit of normal (ULN); (Exception: Participants with documented Gilbert’s syndrome may be eligible if total bilirubin is ≤3×ULN and direct bilirubin is within normal limits [≤ULN]); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN OR ≤5×ULN for participants with liver metastases; Coagulation; International normalized ratio, prothrombin time (PT), partial thromboplastin time (PTT), or activated partial thromboplastin time (aPTT) ≤1.5×ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.","principalInclusionCriteriaTranslations":[{"id":12576839,"uuid":"5c754b23-9204-4c3d-a329-a0e5c0fdfb2c","attributeTranslation":"10. Le/la participant(e) présente une fonction organique adéquate, définie comme suit : Paramètres hématologiques : numération absolue des neutrophiles (NAN) ≥ 1 500/μl (1,5 × 10⁹/l) ; plaquettes ≥ 100 000/μl (100 × 10⁹/l) ; hémoglobine ≥ 9 g/dl (90 g/l) ou ≥ 5,6 mmol/l. Ce critère doit être satisfait sans transfusion de concentrés de globules rouges au cours des 7 jours précédents. Au niveau rénal : Clairance de la créatinine (ClCr) mesurée ou calculée conformément aux pratiques de l’établissement (ClCr ou débit de filtration glomérulaire estimé en ml/min) Au niveau hépatique : Bilirubine sérique totale ≤ 1,5 × limite supérieure de la normale (LSN) ; (exception : les participants présentant un syndrome de Gilbert documenté peuvent être éligibles si la bilirubine totale est ≤ 3 × LSN et si la bilirubine directe se situe dans les limites de la normale [≤ LSN]) ; aspartate aminotransférase (ASAT) et alanine aminotransférase (ALAT) ≤ 2,5 × LSN OU ≤ 5 × LSN chez les participants présentant des métastases hépatiques ; coagulation ; rapport international normalisé (INR), temps de prothrombine (TP) ou temps de céphaline activée (TCA) ≤ 1,5 × LSN, sauf si le/la participant(e) reçoit un traitement anticoagulant, à condition que le TP ou le TCA se situe dans l’intervalle thérapeutique correspondant à l’utilisation prévue des anticoagulants","language":34,"languageDescription":"French (France)"},{"id":12576840,"uuid":"5c754b23-9204-4c3d-a329-a0e5c0fdfb2c","attributeTranslation":"10. El participante presenta una función orgánica adecuada, que se define por: Hematológica: recuento absoluto de neutrófilos (RAN) ≥1500/μl (1,5 × 10^9/l); plaquetas ≥100 000/μl (100 × 10^9/l); hemoglobina ≥9 g/dl (90 g/l) o ≥5,6 mmol/l. Deben reunirse los criterios sin transfusión de concentrado de eritrocitos en los 7 días anteriores. Renal: aclaramiento de creatinina (ACr) medido o calculado según las normas de cada centro (ACr o filtración glomerular estimada, ml/min). Hepática: bilirrubina sérica total ≤1,5 veces el límite superior de la normalidad (LSN); (excepción: los participantes con síndrome de Gilbert documentado pueden ser elegibles si la bilirrubina total es ≤3 veces el LSN y la bilirrubina directa se encuentra dentro de los límites normales [≤LSN]; la aspartato aminotransferasa (ASAT) y la alanina aminotransferasa (ALAT), ≤2,5 veces el LSN o bien ≤5 veces el LSN para los participantes con metástasis hepáticas; coagulación; índice internacional normalizado, tiempo de protrombina (TP), tiempo de tromboplastina parcial (TTP) o tiempo de tromboplastina parcial activada (TTPa) ≤1,5 veces el LSN, salvo que el participante esté recibiendo terapia anticoagulante, siempre que el TP o el TTPa se encuentren dentro del margen terapéutico previsto para el uso de anticoagulantes.","language":7,"languageDescription":"Spanish"},{"id":12576841,"uuid":"5c754b23-9204-4c3d-a329-a0e5c0fdfb2c","attributeTranslation":"10. De deelnemer heeft adequate orgaanfunctie, gedefinieerd als volgt: Hematologisch: absoluut aantal neutrofielen (ANC) ≥1500/μl (1,5×10^9/l); bloedplaatjes ≥100.000/μL (100×10^9/l); hemoglobine ≥9 g/dl (90 g/l) of ≥5,6 mmol/l. Aan deze criteria moet zijn voldaan zonder dat er in de afgelopen 7 dagen een transfusie van erytrocytenconcentraat heeft plaatsgevonden. Nieren: Creatinineklaring (CrCl), gemeten of berekend volgens de normen van de instelling (CrCl of geschatte glomerulaire filtratiesnelheid in ml/min). Lever: Totaal bilirubine in serum ≤1,5×bovengrens van normaal (ULN); (Uitzondering: deelnemers bij wie het syndroom van Gilbert is vastgesteld, kunnen in aanmerking komen indien het totale bilirubine ≤3×ULN bedraagt en het directe bilirubine binnen de normale waarden ligt [≤ULN]); aspartaataminotransferase (ASAT) en alanineaminotransferase (ALAT) ≤2,5×ULN OF ≤5×ULN voor deelnemers met levermetastasen; Stolling: internationale genormaliseerde ratio, protrombinetijd (PT), partiële tromboplastinetijd (PTT) of geactiveerde partiële tromboplastinetijd (aPTT) ≤1,5×ULN, tenzij de deelnemer een antistollingstherapie ondergaat, mits de PT of aPTT binnen het therapeutische bereik ligt dat is bedoeld voor het gebruik van antistollingsmiddelen.","language":18,"languageDescription":"Dutch"},{"id":12576842,"uuid":"5c754b23-9204-4c3d-a329-a0e5c0fdfb2c","attributeTranslation":"10. Odpowiednia wydolność narządów uczestnika, zdefiniowana następująco: Parametry hematologiczne: Bezwzględna liczba neutrofilów (ANC) ≥1500/μl (1,5 × 10^9/l); płytki krwi ≥100 000/μl (100 × 10^9/l); stężenie hemoglobiny ≥9 g/dl (90 g/l) lub ≥5,6 mmol/l. Parametry te muszą być osiągnięte bez przetoczenia koncentratu krwinek czerwonych w okresie ostatnich 7 dni. Nerki: Klirens kreatyniny (CrCl) zmierzony lub obliczony zgodnie ze standardami obowiązującymi w danej instytucji (CrCl lub szacunkowy współczynnik filtracji kłębuszkowej w ml/min). Parametry wątrobowe: Stężenie bilirubiny całkowitej w surowicy ≤1,5 × górna granica normy (GGN); (wyjątek: Uczestnicy z udokumentowanym zespołem Gilberta mogą kwalifikować się do badania, jeśli stężenie bilirubiny całkowitej wynosi ≤3 × GGN, a stężenie bilirubiny bezpośredniej mieści się w granicach normy [≤GGN]). Aktywność aminotransferazy asparaginianowej (AST) i aminotransferazy alaninowej (ALT) ≤2,5 × GGN LUB ≤5 × GGN u uczestników z przerzutami do wątroby. Parametry układu krzepnięcia: międzynarodowy współczynnik znormalizowany, czas protrombinowy (PT), czas częściowej tromboplastyny (PTT) lub czas częściowej tromboplastyny po aktywacji (aPTT) ≤1,5 × GGN, chyba że uczestnik otrzymuje leczenie przeciwzakrzepowe, o ile PT lub aPTT pozostają w zakresie terapeutycznym dla zamierzonego stosowania leków przeciwzakrzepowych.","language":19,"languageDescription":"Polish"}]},{"id":1006712,"number":11,"principalInclusionCriteria":"11. Women of childbearing potential (WOCBP) must have a negative highly sensitive serum pregnancy test within 7 days prior to receiving the first dose of study treatment. A urine pregnancy test can be considered if a blood test is not appropriate per local standard of care.","principalInclusionCriteriaTranslations":[{"id":12576845,"uuid":"a1b1aa7b-7dbb-45bd-8230-db678c6dcbe3","attributeTranslation":"11. Les femmes en capacité de procréer doivent présenter un test de grossesse sérique hautement sensible négatif réalisé au cours des 7 jours précédant l’administration de la première dose du traitement à l’étude. Un test de grossesse urinaire peut être envisagé si un test sanguin n’est pas approprié selon la norme de soins locale.","language":34,"languageDescription":"French (France)"},{"id":12576843,"uuid":"a1b1aa7b-7dbb-45bd-8230-db678c6dcbe3","attributeTranslation":"11. Vrouwen die kinderen kunnen krijgen, moeten een negatieve zeer gevoelige serumzwangerschapstest hebben binnen 7 dagen voorafgaand aan de eerste dosis onderzoeksbehandeling. Een urinezwangerschapstest kan worden overwogen indien een bloedtest volgens de lokale zorgstandaard niet aangewezen is.","language":18,"languageDescription":"Dutch"},{"id":12576844,"uuid":"a1b1aa7b-7dbb-45bd-8230-db678c6dcbe3","attributeTranslation":"11. U kobiet zdolnych do posiadania potomstwa wymagany jest ujemny wynik testu ciążowego o wysokiej czułości wykonanego na próbce surowicy w okresie 7 dni przed otrzymaniem pierwszej dawki badanego leku. Można rozważyć wykonanie testu ciążowego z moczu, jeżeli test ciążowy z krwi nie jest właściwy zgodnie z lokalnym standardem opieki medycznej.","language":19,"languageDescription":"Polish"},{"id":12576846,"uuid":"a1b1aa7b-7dbb-45bd-8230-db678c6dcbe3","attributeTranslation":"11. En el caso de las mujeres en edad fértil (MEF), deberán presentar un resultado negativo en una prueba de embarazo en suero de alta sensibilidad en los 7 días anteriores a la administración de la primera dosis del tratamiento del estudio. Podrá admitirse una prueba de embarazo en orina si, según la práctica habitual local, no es adecuado realizar un análisis de sangre.","language":7,"languageDescription":"Spanish"}]},{"id":1006713,"number":12,"principalInclusionCriteria":"12. WOCBP should be willing to use highly effective contraception for birth control or be surgically sterile or abstain from heterosexual activity for the course of the study and are not permitted to donate oocytes during this time. WOCBP are those who have not been surgically sterilized or have not been free from menses for >1 year","principalInclusionCriteriaTranslations":[{"id":12576850,"uuid":"406c3fb9-f912-4ad7-a4c3-113ddd1a0a01","attributeTranslation":"12. Kobiety zdolne do posiadania potomstwa powinny wyrazić gotowość do stosowania wysoce skutecznej metody antykoncepcyjnej, muszą być po zabiegu sterylizacji chirurgicznej lub muszą powstrzymać się od kontaktów heteroseksualnych w trakcie badania, jak też nie mogą oddawać komórek jajowych w tym okresie. Kobiety zdolne do posiadania potomstwa zdefiniowano jako kobiety, które nie zostały poddane sterylizacji chirurgicznej lub u których występowało krwawienie menstruacyjne w okresie ostatniego roku","language":19,"languageDescription":"Polish"},{"id":12576848,"uuid":"406c3fb9-f912-4ad7-a4c3-113ddd1a0a01","attributeTranslation":"12. Les femmes en capacité de procréer doivent accepter d’utiliser une méthode de contraception hautement efficace, ou avoir fait l’objet d’une stérilisation par voie chirurgicale ou s’abstenir de toute activité hétérosexuelle pendant toute la durée de l’étude et ne sont pas autorisées à faire don d’ovocytes pendant cette période. Les femmes en capacité de procréer sont celles qui n’ont pas fait l’objet d’une stérilisation par voie chirurgicale ou qui ne sont pas ménopausées depuis plus d’un an.","language":34,"languageDescription":"French (France)"},{"id":12576847,"uuid":"406c3fb9-f912-4ad7-a4c3-113ddd1a0a01","attributeTranslation":"12. Vrouwen die kinderen kunnen krijgen dienen bereid te zijn om zeer effectieve anticonceptie te gebruiken, chirurgisch gesteriliseerd te zijn of zich gedurende de looptijd van het onderzoek te onthouden van heteroseksuele activiteiten. Ze mogen in deze periode geen eicellen doneren. Vrouwen die kinderen kunnen krijgen zijn vrouwen die niet chirurgisch zijn gesteriliseerd of die niet al >1 jaar geen menstruatie meer hebben gehad","language":18,"languageDescription":"Dutch"},{"id":12576849,"uuid":"406c3fb9-f912-4ad7-a4c3-113ddd1a0a01","attributeTranslation":"12. Las MEF deben estar dispuestas a utilizar métodos anticonceptivos muy eficaces, estar esterilizadas por medios quirúrgicos o abstenerse de mantener relaciones heterosexuales durante el estudio, y no se les permite donar óvulos durante este periodo. Se define como MEF a aquellas que no están esterilizadas por medios quirúrgicos o no hayan estado sin la menstruación durante >1 año.","language":7,"languageDescription":"Spanish"}]},{"id":1006714,"number":13,"principalInclusionCriteria":"13. Male participants must agree to use a condom or to remain abstinent (refrain from heterosexual intercourse) and not donate sperm starting with the first dose of study treatment through X days  after the last dose of study medication.","principalInclusionCriteriaTranslations":[{"id":12576853,"uuid":"368401e1-673e-4ca7-897a-43776faa956e","attributeTranslation":"13. Mężczyźni uczestniczący w badaniu muszą wyrazić zgodę na stosowanie prezerwatyw lub zachowanie abstynencji seksualnej (powstrzymanie się od stosunków heteroseksualnych) i nie mogą oddawać nasienia od chwili przyjęcia pierwszej dawki badanego leczenia do upłynięcia X dni po przyjęciu ostatniej dawki badanego leku.","language":19,"languageDescription":"Polish"},{"id":12576854,"uuid":"368401e1-673e-4ca7-897a-43776faa956e","attributeTranslation":"13. Mannelijke deelnemers moeten ermee instemmen om een condoom te gebruiken of zich te onthouden (zich te onthouden van heteroseksuele geslachtsgemeenschap) en geen sperma te doneren, vanaf de eerste dosis van de onderzoeksbehandeling tot X dagen na de laatste dosis van het onderzoeksmiddel.","language":18,"languageDescription":"Dutch"},{"id":12576852,"uuid":"368401e1-673e-4ca7-897a-43776faa956e","attributeTranslation":"13. Les participants de sexe masculin doivent accepter d’utiliser un préservatif ou de rester abstinents (s’abstenir de rapports hétérosexuels) et ne pas faire de don de sperme à compter de l’administration de la première dose du traitement à l’étude et jusqu’à 'x' jours après l’administration de la dernière dose du traitement à l’étude.","language":34,"languageDescription":"French (France)"},{"id":12576851,"uuid":"368401e1-673e-4ca7-897a-43776faa956e","attributeTranslation":"13. Los participantes varones deben comprometerse a utilizar preservativo o a mantener la abstinencia (abstenerse de mantener relaciones heterosexuales) y a no donar semen desde la primera dosis del tratamiento del estudio hasta los X días posteriores a la última administración de la medicación del estudio.","language":7,"languageDescription":"Spanish"}]},{"id":1006715,"number":2,"principalInclusionCriteria":"2. Participant is ≥18 years of age or of an acceptable age according to local regulations, whichever is older on the day the ICF is signed.","principalInclusionCriteriaTranslations":[{"id":12576855,"uuid":"aba85576-52f1-4ad0-9e90-7980e5002c16","attributeTranslation":"2. De deelnemer is ≥18 jaar oud of heeft een leeftijd die volgens de lokale regelgeving aanvaardbaar is, afhankelijk van welke van beide leeftijden op de dag van ondertekening van de ICF hoger is.","language":18,"languageDescription":"Dutch"},{"id":12576858,"uuid":"aba85576-52f1-4ad0-9e90-7980e5002c16","attributeTranslation":"2. El participante tiene 18 años o más, o bien la edad mínima exigida por la normativa local, la que sea superior, en la fecha de la firma del DCI.","language":7,"languageDescription":"Spanish"},{"id":12576856,"uuid":"aba85576-52f1-4ad0-9e90-7980e5002c16","attributeTranslation":"2. Uczestnik jest w wieku ≥18 lat lub w wieku umożliwiającym wyrażenie zgody zgodnie z lokalnymi przepisami, w zależności od tego, który wiek jest starszy, w dniu podpisania ICF.","language":19,"languageDescription":"Polish"},{"id":12576857,"uuid":"aba85576-52f1-4ad0-9e90-7980e5002c16","attributeTranslation":"2. Le/la participant(e) est âgé(e) de 18 ans ou plus, ou a atteint l’âge minimum légal selon la réglementation locale, l’âge le plus élevé étant retenu, à la date de signature du FCE.","language":34,"languageDescription":"French (France)"}]},{"id":1006716,"number":3,"principalInclusionCriteria":"3. Participant has histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx, or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: Primary tumor locations of paranasal sinuses and nasopharynx or tumor of any other histology are excluded.","principalInclusionCriteriaTranslations":[{"id":12576860,"uuid":"19b7d43f-4b3b-4f98-99b7-faf6be3781f0","attributeTranslation":"3. El participante tiene CECC R o M confirmado mediante estudio histológico o citológico. Las localizaciones del tumor primario que cumplen los criterios de inclusión son la cavidad bucal, la hipofaringe, la laringe o la orofaringe (con enfermedad documentada como negativa para el VPH en caso de presentar carcinoma epidermoide orofaríngeo [CEOF]). Nota: Se excluyen los tumores primarios localizados en los senos paranasales y la nasofaringe, así como los tumores de cualquier otro tipo histológico.","language":7,"languageDescription":"Spanish"},{"id":12576859,"uuid":"19b7d43f-4b3b-4f98-99b7-faf6be3781f0","attributeTranslation":"3. Le/la participant(e) présente un CETC récidivant ou métastatique confirmé par examen histologique ou cytologique. Les localisations tumorales primitives éligibles sont la cavité buccale, l’hypopharynx, le larynx ou l’oropharynx (avec documentation d’un statut HPV négatif en cas de carcinome épidermoïde de l’oropharynx [CEOP]). Remarque : les tumeurs primitives des sinus paranasaux et du nasopharynx ainsi que les tumeurs présentant toute autre histologie sont exclues.","language":34,"languageDescription":"French (France)"},{"id":12576861,"uuid":"19b7d43f-4b3b-4f98-99b7-faf6be3781f0","attributeTranslation":"3. U uczestnika występuje potwierdzony histologicznie lub cytologicznie nawrotowy (R) lub przerzutowy (M) rak płaskonabłonkowy głowy i szyi (HNSCC). Kwalifikującymi się lokalizacjami guza pierwotnego są: jama ustna, część krtaniowa gardła, krtań lub część ustna gardła (z udokumentowaną chorobą HPV‑ujemną w przypadku występowania raka płaskonabłonkowego jamy ustnej i gardła (OPSCC)). Uwaga: Lokalizacja guza pierwotnego w zatokach obocznych nosa i nosogardzieli lub guz o dowolnym innym typie histologicznym stanowią kryteria wykluczające.","language":19,"languageDescription":"Polish"},{"id":12576862,"uuid":"19b7d43f-4b3b-4f98-99b7-faf6be3781f0","attributeTranslation":"3. De deelnemer heeft histologisch of cytologisch bevestigd recidiverend (R) of gemetastaseerd (M) HNSCC. In aanmerking komende locaties van de primaire tumor zijn de mondholte, hypofarynx, larynx of orofarynx (met gedocumenteerde HPV-negatieve ziekte in geval van OPSCC). Opmerking: Locaties van de primaire tumor in de neusbijholten en de nasofarynx, of tumoren met een andere histologie, worden uitgesloten.","language":18,"languageDescription":"Dutch"}]},{"id":1006717,"number":4,"principalInclusionCriteria":"4. No prior systemic therapy administered in the R  or M setting. Systemic therapy completed >6 months prior to signing ICF if given as part of multimodal treatment for locoregionally advanced disease is allowed.","principalInclusionCriteriaTranslations":[{"id":12576864,"uuid":"703b7c39-2685-4672-8ea7-f07b64f9a86b","attributeTranslation":"4. Er is geen eerdere systemische behandeling toegediend in de R- of M-setting. Systemische therapie die >6 maanden vóór de ondertekening van het PIF is afgerond, is toegestaan indien deze is toegediend als onderdeel van een multimodale behandeling voor locoregionaal gevorderde ziekte.","language":18,"languageDescription":"Dutch"},{"id":12576865,"uuid":"703b7c39-2685-4672-8ea7-f07b64f9a86b","attributeTranslation":"4. Niestosowanie wcześniej leczenia ogólnoustrojowego w stadium R lub M. Dozwolone jest leczenie ogólnoustrojowe zakończone >6 miesięcy przed podpisaniem ICF, jeśli jest stosowane w ramach leczenia multimodalnego choroby lokoregionalnie zaawansowanej.","language":19,"languageDescription":"Polish"},{"id":12576866,"uuid":"703b7c39-2685-4672-8ea7-f07b64f9a86b","attributeTranslation":"4. Aucun traitement systémique antérieur administré dans le contexte d’une maladie récidivante ou métastatique. Un traitement systémique terminé plus de 6 mois avant la signature du FCE est autorisé s’il a été administré dans le cadre d’un traitement multimodal d’une maladie localement avancée avec extension régionale.","language":34,"languageDescription":"French (France)"},{"id":12576863,"uuid":"703b7c39-2685-4672-8ea7-f07b64f9a86b","attributeTranslation":"4. No se ha administrado ninguna terapia sistémica anterior para la enfermedad R o M. Se permite la terapia sistémica que haya finalizado >6 meses antes de la firma del DCI, siempre que se haya administrado como parte de un tratamiento multimodal para una enfermedad locorregionalmente avanzada.","language":7,"languageDescription":"Spanish"}]},{"id":1006718,"number":5,"principalInclusionCriteria":"5. Participant is willing to provide archival tumor tissue as specified in the laboratory manual or willing to undergo pretreatment excisional or core needle biopsy (fine needle aspirates not acceptable) at Screening if archival tissue is insufficient or unavailable.","principalInclusionCriteriaTranslations":[{"id":12576870,"uuid":"306cd52a-13a1-471b-9c35-cefc6800a2a9","attributeTranslation":"5. Uczestnik musi wyrażać gotowość przekazania archiwalnej tkanki nowotworowej, jak określono w instrukcji laboratoryjnej, bądź musi wyrażać gotowość poddania się biopsji wycinającej lub biopsji gruboigłowej wykonanej przed leczeniem (aspiraty cienkoigłowe nie są akceptowane) podczas oceny przesiewowej, jeżeli archiwalna tkanka jest niewystarczająca lub niedostępna.","language":19,"languageDescription":"Polish"},{"id":12576867,"uuid":"306cd52a-13a1-471b-9c35-cefc6800a2a9","attributeTranslation":"Le/la participant(e) accepte de fournir un échantillon tumoral archivé conformément aux spécifications du manuel de laboratoire ou accepte de se prêter, pendant la période de sélection, à une biopsie-exérèse ou une microbiopsie avant le traitement (les ponctions à l’aiguille fine ne sont pas acceptées) si le tissu archivé est insuffisant ou indisponible.","language":34,"languageDescription":"French (France)"},{"id":12576869,"uuid":"306cd52a-13a1-471b-9c35-cefc6800a2a9","attributeTranslation":"5. El participante está dispuesto a proporcionar tejido tumoral de archivo tal como se especifica en el manual de laboratorio, o bien a someterse a una biopsia por escisión o con aguja gruesa antes del tratamiento (no se aceptan los aspirados con aguja fina) en la selección, en caso de que no se disponga de tejido de archivo o este sea insuficiente.","language":7,"languageDescription":"Spanish"},{"id":12576868,"uuid":"306cd52a-13a1-471b-9c35-cefc6800a2a9","attributeTranslation":"5. De deelnemer is bereid om gearchiveerd tumorweefsel ter beschikking te stellen zoals aangegeven in het laboratoriumhandboek, of is bereid om tijdens de screening een excisiebiopsie of kernnaaldbiopsie te ondergaan (fijne naaldaspiraties zijn niet toegestaan) indien het gearchiveerde weefsel onvoldoende of niet beschikbaar is.","language":18,"languageDescription":"Dutch"}]},{"id":1006719,"number":6,"principalInclusionCriteria":"6. Participants presenting with primary tumor location in oropharynx must have documentation of HPV-negative disease as determined by a validated test.","principalInclusionCriteriaTranslations":[{"id":12576873,"uuid":"b7a3b042-d2e1-4a7a-89e9-81255a2cbaea","attributeTranslation":"6. Los participantes cuyo tumor primario se localice en la orofaringe deben presentar documentación que acredite que la enfermedad es negativa para el VPH, según lo determine una prueba validada.","language":7,"languageDescription":"Spanish"},{"id":12576871,"uuid":"b7a3b042-d2e1-4a7a-89e9-81255a2cbaea","attributeTranslation":"6. Deelnemers bij wie de primaire tumor zich in de orofarynx bevindt, moeten kunnen aantonen dat hun aandoening HPV-negatief is, zoals vastgesteld door middel van een gevalideerde test.","language":18,"languageDescription":"Dutch"},{"id":12576874,"uuid":"b7a3b042-d2e1-4a7a-89e9-81255a2cbaea","attributeTranslation":"6. Les participants présentant une tumeur primitive localisée dans l’oropharynx doivent justifier d’un statut HPV négatif, tel que déterminé par un test validé.","language":34,"languageDescription":"French (France)"},{"id":12576872,"uuid":"b7a3b042-d2e1-4a7a-89e9-81255a2cbaea","attributeTranslation":"6. U uczestników z lokalizacją guza pierwotnego w części ustnej gardła wymagane jest udokumentowanie ujemnego statusu HPV, określonego przy użyciu zwalidowanego testu.","language":19,"languageDescription":"Polish"}]},{"id":1006720,"number":7,"principalInclusionCriteria":"7. Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (by PD-L1 immunohistochemistry [IHC] 22C3), determined locally or centrally.","principalInclusionCriteriaTranslations":[{"id":12576876,"uuid":"b5555510-09c7-46ea-a0ac-1f1d70e32e21","attributeTranslation":"7. Le/la participant(e) est éligible à un traitement de première ligne par pembrolizumab en monothérapie et présente un CPS PD-L1 tumoral documenté ≥ 1 (par immunohistochimie [IHC] PD-L1 22C3), déterminé localement ou de façon centralisée.","language":34,"languageDescription":"French (France)"},{"id":12576875,"uuid":"b5555510-09c7-46ea-a0ac-1f1d70e32e21","attributeTranslation":"7. De deelnemer komt in aanmerking voor behandeling met pembrolizumab als eerstelijnsmonotherapie bij een gedocumenteerde PD-L1-CPS van de tumor van ≥1 (bepaald aan de hand van PD-L1-immunohistochemie [IHC] 22C3), lokaal of centraal vastgesteld.","language":18,"languageDescription":"Dutch"},{"id":12576877,"uuid":"b5555510-09c7-46ea-a0ac-1f1d70e32e21","attributeTranslation":"7. El participante es apto para recibir pembrolizumab en monoterapia de primera línea si presenta una PPC del PD-L1 ≥1 documentada en el tumor (mediante inmunohistoquímica [IHC] del PD-L1 22C3), determinada de forma local o central.","language":7,"languageDescription":"Spanish"},{"id":12576878,"uuid":"b5555510-09c7-46ea-a0ac-1f1d70e32e21","attributeTranslation":"7. Uczestnik kwalifikuje się do otrzymywania pembrolizumabu w monoterapii pierwszej linii z udokumentowaną wartością CPS PD‑L1 w guzie ≥1 (na podstawie testu immunohistochemicznego [IHC] PD‑L1 22C3), w ocenie wykonanej lokalnie lub centralnie.","language":19,"languageDescription":"Polish"}]},{"id":1006721,"number":8,"principalInclusionCriteria":"8. Participant has measurable disease based on RECIST 1.1 as determined by BICR. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated. Baseline Scan must be transferred to BICR for assessment.","principalInclusionCriteriaTranslations":[{"id":12576880,"uuid":"e3db138c-e4ef-4493-8ef6-7fc8bba0ed9f","attributeTranslation":"8. De deelnemer heeft een meetbare ziekte op basis van RECIST v1.1 zoals bepaald door BICR. Tumorlaesies in een eerder bestraald gebied worden als meetbaar beschouwd als progressie is aangetoond. De scan bij baseline moet ter beoordeling worden doorgestuurd voor BICR.","language":18,"languageDescription":"Dutch"},{"id":12576882,"uuid":"e3db138c-e4ef-4493-8ef6-7fc8bba0ed9f","attributeTranslation":"8. El participante presenta enfermedad mensurable según RECIST 1.1 determinada por evaluación central independiente con enmascaramiento (ECIE). Las lesiones tumorales situadas en una zona previamente irradiada se consideran mensurables si se ha demostrado su progresión. La exploración basal debe enviarse y someterse a una ECIE.","language":7,"languageDescription":"Spanish"},{"id":12576879,"uuid":"e3db138c-e4ef-4493-8ef6-7fc8bba0ed9f","attributeTranslation":"8. U uczestnika występuje mierzalna choroba według kryteriów RECIST w wersji 1.1 w ocenie BICR. Ogniska docelowe zlokalizowane w polu wcześniej napromienianym są uznawane za mierzalne, jeżeli w obrębie tych ognisk wykazano progresję po napromienianiu. Wyjściowe badanie obrazowe należy przesłać do oceny BICR.","language":19,"languageDescription":"Polish"},{"id":12576881,"uuid":"e3db138c-e4ef-4493-8ef6-7fc8bba0ed9f","attributeTranslation":"8. Le/la participant(e) présente une maladie mesurable selon les critères RECIST 1.1, déterminée par la RCIA. Les lésions tumorales situées dans une zone précédemment irradiée sont considérées comme mesurables si une progression a été démontrée. L’examen d’imagerie de référence doit être transmis à la RCIA pour évaluation.","language":34,"languageDescription":"French (France)"}]},{"id":1006722,"number":9,"principalInclusionCriteria":"9. Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.","principalInclusionCriteriaTranslations":[{"id":12576885,"uuid":"23fd8f98-a2f5-4aa5-a2a4-87c87def5a81","attributeTranslation":"9. Le/la participant(e) présente un indice de performance ECOG (Eastern Cooperative Oncology Group) de 0 ou 1.","language":34,"languageDescription":"French (France)"},{"id":12576884,"uuid":"23fd8f98-a2f5-4aa5-a2a4-87c87def5a81","attributeTranslation":"9. De deelnemer heeft een ECOG-prestatiescore (Eastern Cooperative Oncology Group) van 0-1.","language":18,"languageDescription":"Dutch"},{"id":12576886,"uuid":"23fd8f98-a2f5-4aa5-a2a4-87c87def5a81","attributeTranslation":"9. Stan sprawności w skali Eastern Cooperative Oncology Group (ECOG) oceniony na 0 lub 1.","language":19,"languageDescription":"Polish"},{"id":12576883,"uuid":"23fd8f98-a2f5-4aa5-a2a4-87c87def5a81","attributeTranslation":"9. El participante presenta un estado funcional según la escala del Eastern Cooperative Oncology Group (grupo oncológico cooperativo del Este [ECOG]) de 0 o 1.","language":7,"languageDescription":"Spanish"}]}],"principalExclusionCriteria":[{"id":1717692,"number":1,"principalExclusionCriteria":"1. Prior systemic therapy in the R or M setting.","principalExclusionCriteriaTranslations":[{"id":12576733,"uuid":"0e34bb73-165a-449f-9480-4ce2ef8e88fa","attributeTranslation":"1. Eerdere systemische behandeling in de R- of M-setting.","language":18,"languageDescription":"Dutch"},{"id":12576734,"uuid":"0e34bb73-165a-449f-9480-4ce2ef8e88fa","attributeTranslation":"1. Terapia sistémica anterior para la enfermedad R o M.","language":7,"languageDescription":"Spanish"},{"id":12576732,"uuid":"0e34bb73-165a-449f-9480-4ce2ef8e88fa","attributeTranslation":"1. Wcześniejsze leczenie ogólnoustrojowe w stadium R lub M.","language":19,"languageDescription":"Polish"},{"id":12576731,"uuid":"0e34bb73-165a-449f-9480-4ce2ef8e88fa","attributeTranslation":"1. Traitement systémique antérieur administré dans le contexte d’une maladie récidivante ou métastatique.","language":34,"languageDescription":"French (France)"}]},{"id":1717693,"number":10,"principalExclusionCriteria":"10. Any of the following <6 months before starting study treatment: ST-elevation myocardial infarction, severe/unstable angina, uncontrolled cardiac ventricular arrythmia, coronary/peripheral artery bypass graft or stent, cerebrovascular accident/stroke less than 6 months prior to enrollment or New York Heart Association Class III/IV congestive heart failure. Participants with deep vein thrombosis who are hemodynamically stable can enroll if they are on a stable dose of anticoagulants for at least 3 months.","principalExclusionCriteriaTranslations":[{"id":12576736,"uuid":"0db31575-c798-4132-bfdb-02c026e7e6ca","attributeTranslation":"10. Een van de volgende <6 maanden vóór aanvang van de onderzoeksbehandeling: Myocardinfarct met ST-elevatie, ernstige/instabiele angina pectoris, ventriculaire hartritmestoornis die niet onder controle is, coronaire of perifere arteriële bypassoperatie of stent, cerebrovasculair incident/beroerte minder dan 6 maanden vóór de inschrijving, of congestief hartfalen van New York Heart Association klasse III/IV. Deelnemers met diepveneuze trombose die hemodynamisch stabiel zijn, komen in aanmerking voor deelname indien zij gedurende ten minste 3 maanden een stabiele dosis antistollingsmiddelen hebben gebruikt.","language":18,"languageDescription":"Dutch"},{"id":12576737,"uuid":"0db31575-c798-4132-bfdb-02c026e7e6ca","attributeTranslation":"10. Présence de l’un des événements suivants au cours des 6 mois précédant le début du traitement à l’étude : infarctus du myocarde avec sus-décalage du segment ST, angor sévère/instable, arythmie ventriculaire non contrôlée, pontage artériel coronaire/périphérique ou pose d’un stent, accident vasculaire cérébral (AVC) survenu moins de 6 mois avant l’inclusion ou insuffisance cardiaque congestive de classe III ou IV selon la New York Heart Association. Les participants présentant une thrombose veineuse profonde peuvent être inclus s’ils sont stables sur le plan hémodynamique et s’ils suivent un traitement anticoagulant à dose stable depuis au moins 3 mois.","language":34,"languageDescription":"French (France)"},{"id":12576738,"uuid":"0db31575-c798-4132-bfdb-02c026e7e6ca","attributeTranslation":"10. Cualquiera de los siguientes casos <6 meses antes de iniciar el tratamiento del estudio: infarto de miocardio con elevación del segmento ST, angina de pecho grave/inestable, arritmia ventricular cardíaca no controlada, revascularización o endoprótesis coronaria/periférica, accidente cerebrovascular o ictus ocurrido menos de 6 meses antes de la inclusión o insuficiencia cardíaca congestiva de clase III o IV según la clasificación de la Asociación de Cardiología de Nueva York. Los participantes con trombosis venosa profunda que se encuentren emodinámicamente estables podrán participar si llevan al menos 3 meses tomando una dosis estable de anticoagulantes.","language":7,"languageDescription":"Spanish"},{"id":12576735,"uuid":"0db31575-c798-4132-bfdb-02c026e7e6ca","attributeTranslation":"10. Dowolne z następujących zdarzeń w okresie <6 miesięcy przed rozpoczęciem badanego leczenia: Zawał mięśnia sercowego z uniesieniem odcinka ST, ciężka/niestabilna dławica piersiowa, niewyrównane komorowe zaburzenia rytmu serca, pomostowanie tętnic wieńcowych/obwodowych lub wszczepienie stentu, incydent naczyniowo‑mózgowy/udar mózgu w okresie 6 miesięcy przed włączeniem do badania lub zastoinowa niewydolność serca klasy III/IV według Nowojorskiego Towarzystwa Kardiologicznego. Uczestnicy z zakrzepicą żył głębokich, których stan hemodynamiczny jest stabilny, mogą być kwalifikowani do badania, jeżeli otrzymują stabilną dawkę leków przeciwzakrzepowych przez co najmniej 3 miesiące.","language":19,"languageDescription":"Polish"}]},{"id":1717694,"number":11,"principalExclusionCriteria":"11. Major surgery (including eye surgery) or palliative radiotherapy <2 weeks prior to enrollment. Participants must have recovered adequately from any surgery (major or minor) or radiation and/or its complications before enrollment.","principalExclusionCriteriaTranslations":[{"id":12576742,"uuid":"0a6450c7-4621-408d-880b-00c542442dc1","attributeTranslation":"11. Ingrijpende operatie (waaronder oogoperatie) of palliatieve radiotherapie binnen 2 weken voorafgaand aan inschrijving. Deelnemers moeten vóór hun inschrijving voldoende hersteld zijn van een eventuele operatie (groot of klein) of bestraling en/of de complicaties daarvan.","language":18,"languageDescription":"Dutch"},{"id":12576739,"uuid":"0a6450c7-4621-408d-880b-00c542442dc1","attributeTranslation":"11. Intervention chirurgicale majeure (y compris chirurgie oculaire) ou radiothérapie palliative < 2 semaines avant l’inclusion. Les participants doivent avoir récupéré de manière satisfaisante de toute intervention chirurgicale (majeure ou mineure), de toute radiothérapie et/ou de leurs complications avant l’inclusion.","language":34,"languageDescription":"French (France)"},{"id":12576740,"uuid":"0a6450c7-4621-408d-880b-00c542442dc1","attributeTranslation":"11. Cirugía mayor (incluida la cirugía ocular) o radioterapia paliativa en <2 semanas antes de la inclusión. Los participantes deben haberse recuperado adecuadamente de cualquier intervención quirúrgica (mayor o menor) o de la radioterapia o de sus complicaciones antes de la inclusión.","language":7,"languageDescription":"Spanish"},{"id":12576741,"uuid":"0a6450c7-4621-408d-880b-00c542442dc1","attributeTranslation":"11. Poważny zabieg chirurgiczny (w tym operacja oka) lub radioterapia paliatywna w okresie <2 tygodni przed włączeniem do badania. U uczestników muszą w wystarczającym stopniu ustąpić wszystkie skutki zabiegu chirurgicznego (poważnego lub innego) lub radioterapii i/lub ich powikłania przed włączeniem do badania.","language":19,"languageDescription":"Polish"}]},{"id":1717695,"number":12,"principalExclusionCriteria":"12. Participants who participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy or at least 4 weeks if the half-life of the agent received is not known before enrollment","principalExclusionCriteriaTranslations":[{"id":12576744,"uuid":"570acb52-956d-46cf-8b64-b1d846594845","attributeTranslation":"12. Les participants ayant participé à une autre étude clinique ou ayant reçu un autre traitement expérimental doivent respecter un délai d’au moins 5 demi-vies du traitement reçu ou de 4 semaines (la période la plus courte étant retenue) après le traitement antérieur, ou d’au moins 4 semaines si la demi-vie de l’agent reçu n’est pas connue avant l’inclusion.","language":34,"languageDescription":"French (France)"},{"id":12576746,"uuid":"570acb52-956d-46cf-8b64-b1d846594845","attributeTranslation":"12. Deelnemers die aan een ander klinisch onderzoek hebben deelgenomen of zijn behandeld met een ander onderzoeksmiddel, moeten na de eerdere behandeling ten minste 5 halfwaardetijden van het toegediende middel of 4 weken wachten (afhankelijk van welke periode korter is), of ten minste 4 weken indien de halfwaardetijd van het toegediende middel niet bekend is, voordat ze kunnen worden ingeschreven in het onderzoek","language":18,"languageDescription":"Dutch"},{"id":12576743,"uuid":"570acb52-956d-46cf-8b64-b1d846594845","attributeTranslation":"12. Uczestnicy, którzy uczestniczyli w innym badaniu klinicznym lub otrzymywali leczenie innym lekiem eksperymentalnym, muszą odczekać co najmniej 5 okresów półtrwania otrzymanego leczenia lub 4 tygodnie (w zależności od tego, który okres jest krótszy) po wcześniejszym leczeniu lub co najmniej 4 tygodnie, jeżeli okres półtrwania otrzymanego leku nie jest znany przed włączeniem do badania.","language":19,"languageDescription":"Polish"},{"id":12576745,"uuid":"570acb52-956d-46cf-8b64-b1d846594845","attributeTranslation":"12. Los participantes que hayan participado en otro estudio clínico o hayan recibido tratamiento con otro medicamento en fase de investigación clínica deben esperar al menos 5 semividas del tratamiento recibido o 4 semanas (lo que sea más corto) tras a terapia previa, o al menos 4 semanas, si se desconoce la semivida del fármaco recibido, antes de su inclusión.","language":7,"languageDescription":"Spanish"}]},{"id":1717696,"number":13,"principalExclusionCriteria":"13. Active autoimmune disease requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.","principalExclusionCriteriaTranslations":[{"id":12576748,"uuid":"b0211672-f12c-48bc-817e-36cc3750cd7f","attributeTranslation":"13. Actieve auto-immuunziekte waarvoor een systemische behandeling nodig is in de afgelopen 2 jaar (d.w.z. met gebruik van ziektemodificerende middelen, corticosteroïden of immunosuppressiva). Vervangingstherapie (bijv. thyroxine, insuline of fysiologische corticosteroïdenvervangingstherapie voor bijnierschors- of hypofyse-insufficiëntie, etc.) wordt niet beschouwd als een vorm van systemische behandeling","language":18,"languageDescription":"Dutch"},{"id":12576747,"uuid":"b0211672-f12c-48bc-817e-36cc3750cd7f","attributeTranslation":"13. Aktywna choroba autoimmunologiczna wymagająca leczenia ogólnoustrojowego w okresie ostatnich 2 lat (tj. leczenia z użyciem leków modyfikujących przebieg choroby, kortykosteroidów lub leków immunosupresyjnych). Terapia zastępcza (z użyciem np. tyroksyny, insuliny bądź fizjologicznej terapii zastępczej kortykosteroidami z powodu niewydolności kory nadnerczy lub przysadki mózgowej itp.) nie jest uważana za formę leczenia ogólnoustrojowego.","language":19,"languageDescription":"Polish"},{"id":12576749,"uuid":"b0211672-f12c-48bc-817e-36cc3750cd7f","attributeTranslation":"13. Enfermedad autoinmunitaria activa que haya requerido tratamiento sistémico en los últimos 2 años (es decir, con el uso de fármacos modificadores de la enfermedad, corticosteroides o inmunodepresores). El tratamiento de reposición (p. ej., tiroxina, insulina o tratamiento de reposición con corticoesteroides fisiológicos por insuficiencia suprarrenal o hipofisaria, etc.) no se considera un tipo de tratamiento sistémico.","language":7,"languageDescription":"Spanish"},{"id":12576750,"uuid":"b0211672-f12c-48bc-817e-36cc3750cd7f","attributeTranslation":"13. Maladie auto-immune active ayant nécessité un traitement systémique au cours des 2 dernières années (c.-à-d. par des agents modificateurs de la maladie, corticoïdes ou immunosuppresseurs). Un traitement substitutif (p. ex. thyroxine, insuline ou corticothérapie substitutive physiologique pour une insuffisance surrénalienne ou hypophysaire, etc.) n’est pas considéré comme une forme de traitement systémique.","language":34,"languageDescription":"French (France)"}]},{"id":1717697,"number":14,"principalExclusionCriteria":"14. Serious systemic infection (bacterial, viral, or fungal) within 4 weeks before first dose of study treatment, or active systemic infection requiring either hospitalization or parenteral anti-infective therapy within 2 weeks before first dose of study treatment.","principalExclusionCriteriaTranslations":[{"id":12576754,"uuid":"3084d89a-ec43-48be-b7ae-928ac012e2f4","attributeTranslation":"14. Infection systémique grave (bactérienne, virale ou fongique) au cours des 4 semaines précédant l’administration de la première dose du traitement à l’étude, ou infection systémique active nécessitant une hospitalisation ou un traitement anti-infectieux parentéral au cours des 2 semaines précédant l’administration de la première dose du traitement à l’étude.","language":34,"languageDescription":"French (France)"},{"id":12576752,"uuid":"3084d89a-ec43-48be-b7ae-928ac012e2f4","attributeTranslation":"14. Infección sistémica grave (bacteriana, vírica o fúngica) en las 4 semanas previas a la primera dosis del tratamiento del estudio, o infección sistémica activa que haya requerido hospitalización o terapia antinfecciosa parenteral en las 2 semanas previas a la primera dosis del tratamiento del estudio.","language":7,"languageDescription":"Spanish"},{"id":12576753,"uuid":"3084d89a-ec43-48be-b7ae-928ac012e2f4","attributeTranslation":"14. Een ernstige systemische infectie (bacterieel, viraal of schimmel) binnen 4 weken vóór de eerste dosis van de onderzoeksbehandeling, of een actieve systemische infectie waarvoor ziekenhuisopname of parenterale anti-infectieuze therapie nodig was binnen 2 weken vóór de eerste dosis onderzoeksbehandeling.","language":18,"languageDescription":"Dutch"},{"id":12576751,"uuid":"3084d89a-ec43-48be-b7ae-928ac012e2f4","attributeTranslation":"14. Ciężkie zakażenie ogólnoustrojowe (bakteryjne, wirusowe lub grzybicze) w okresie 4 tygodni przed podaniem pierwszej dawki badanego leczenia lub aktywne zakażenie ogólnoustrojowe wymagające hospitalizacji lub leczenia przeciwzakaźnego podawanego drogą pozajelitową w okresie 2 tygodni przed podaniem pierwszej dawki badanego leczenia.","language":19,"languageDescription":"Polish"}]},{"id":1717698,"number":15,"principalExclusionCriteria":"15. Known psychiatric, behavioral, or substance abuse disorders that would interfere with cooperation of the study requirements.","principalExclusionCriteriaTranslations":[{"id":12576758,"uuid":"19f70661-9e3e-4cf4-b6f0-e4171a5a60c8","attributeTranslation":"15. Een bekende psychiatrische of gedragsstoornissen of stoornissen in het gebruik van middelen waardoor het meewerken aan de vereisten van het onderzoek in het geding komt.","language":18,"languageDescription":"Dutch"},{"id":12576755,"uuid":"19f70661-9e3e-4cf4-b6f0-e4171a5a60c8","attributeTranslation":"15. Trastornos psiquiátricos, conductuales o derivados de toxicomanía conocidos que puedan interferir para cumplir los requisitos del estudio.","language":7,"languageDescription":"Spanish"},{"id":12576757,"uuid":"19f70661-9e3e-4cf4-b6f0-e4171a5a60c8","attributeTranslation":"15. Troubles psychiatriques, comportementaux ou liés à la toxicomanie connus, susceptibles d’interférer avec le respect des exigences de l’étude.","language":34,"languageDescription":"French (France)"},{"id":12576756,"uuid":"19f70661-9e3e-4cf4-b6f0-e4171a5a60c8","attributeTranslation":"15. Stwierdzone zaburzenia psychiatryczne, behawioralne lub związane z nadużywaniem substancji psychoaktywnych, które mogą utrudniać współpracę lub przestrzeganie wymagań związanych z badaniem.","language":19,"languageDescription":"Polish"}]},{"id":1717699,"number":16,"principalExclusionCriteria":"16. Participants with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment. Participants who are hepatitis B surface antigen positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment. Note: Participants should remain on antiviral therapy throughout the Treatment Period and follow local guidelines for HBV antiviral therapy post completion of study treatment.","principalExclusionCriteriaTranslations":[{"id":12576760,"uuid":"f8247d62-f66e-450d-b183-3cdafbe8188e","attributeTranslation":"16. Participants présentant une infection chronique par le virus de l’hépatite B (VHB) avec maladie active, répondant aux critères d’un traitement anti-VHB et ne recevant pas de traitement antiviral suppressif avant l’instauration du traitement à l’étude. Les participants positifs pour l’antigène de surface de l’hépatite B sont éligibles s’ils ont reçu un traitement antiviral contre le VHB pendant au moins 4 semaines et s’ils présentent une charge virale VHB indétectable avant l’inclusion. Remarque : les participants devront poursuivre le traitement antiviral pendant toute la période de traitement et suivre les recommandations locales relatives au traitement antiviral contre le VHB après la fin du traitement à l’étude.","language":34,"languageDescription":"French (France)"},{"id":12576759,"uuid":"f8247d62-f66e-450d-b183-3cdafbe8188e","attributeTranslation":"16. Deelnemers met een chronische infectie met het hepatitis B-virus (HBV) met actieve ziekte die voldoen aan de criteria voor een anti-HBV-behandeling en die vóór aanvang van de onderzoeksbehandeling geen suppressieve antivirale therapie krijgen. Deelnemers die positief zijn voor het hepatitis B-oppervlakteantigeen komen in aanmerking indien zij gedurende ten minste 4 weken een antivirale behandeling tegen HBV hebben ondergaan en vóór aanvang van het onderzoek een niet-detecteerbare virale belasting van HBV hebben. Opmerking: De deelnemers dienen gedurende de gehele behandelperiode de antivirale behandeling voort te zetten en na afloop van de onderzoeksbehandeling de lokale richtlijnen voor antivirale behandeling voor HBV te volgen.","language":18,"languageDescription":"Dutch"},{"id":12576762,"uuid":"f8247d62-f66e-450d-b183-3cdafbe8188e","attributeTranslation":"16. Participantes con infección crónica por el virus de la hepatitis B (VHB) en fase activa que cumplan los criterios para recibir terapia contra el VHB y que no estén recibiendo terapia antivírica inhibidora antes del inicio del tratamiento del estudio. Los participantes con resultado positivo para el antígeno de superficie del virus de la hepatitis B podrán participar si han recibido terapia antivírica contra el VHB durante al menos 4 semanas y presentan una carga viral del VHB indetectable antes de la inclusión. Nota: Los participantes deberán continuar con la terapia antivírica durante todo el periodo de tratamiento y cumplir las directrices locales relativas a la terapia antivírica contra el VHB una vez finalizado el tratamiento del estudio.","language":7,"languageDescription":"Spanish"},{"id":12576761,"uuid":"f8247d62-f66e-450d-b183-3cdafbe8188e","attributeTranslation":"16. Uczestnicy z przewlekłym zakażeniem wirusem zapalenia wątroby typu B (HBV) z aktywną chorobą, którzy spełniają kryteria leczenia anty‑HBV i nie stosują supresyjnego leczenia przeciwwirusowego przed rozpoczęciem badanego leczenia. Uczestnicy z dodatnim wynikiem badania w kierunku antygenu powierzchniowego wirusa zapalenia wątroby typu B kwalifikują się do badania, jeśli otrzymywali leczenie przeciwwirusowe przeciwko HBV przez co najmniej 4 tygodnie i przed włączeniem do badania wiremia HBV jest u nich niewykrywalna. Uwaga: Uczestnicy powinni kontynuować leczenie przeciwwirusowe przez cały okres leczenia i przestrzegać lokalnych wytycznych dotyczących leczenia przeciwwirusowego przeciwko HBV po zakończeniu badanego leczenia.","language":19,"languageDescription":"Polish"}]},{"id":1717700,"number":17,"principalExclusionCriteria":"17. Participants with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening. Note: participants must have completed curative antiviral therapy at least 4 weeks prior to enrollment","principalExclusionCriteriaTranslations":[{"id":12576763,"uuid":"d9ec471b-b0ff-4280-80c7-c97a7f4ff499","attributeTranslation":"17. Participants ayant des antécédents connus d’infection par le virus de l’hépatite C (VHC) n’ayant pas terminé un traitement antiviral à visée curative ou présentant une charge virale VHC supérieure à la limite de quantification lors de la sélection. Remarque : les participants doivent avoir terminé leur traitement antiviral à visée curative au moins 4 semaines avant l’inclusion.","language":34,"languageDescription":"French (France)"},{"id":12576766,"uuid":"d9ec471b-b0ff-4280-80c7-c97a7f4ff499","attributeTranslation":"17. Deelnemers met een bekende voorgeschiedenis van het hepatitis C-virus (HCV) zonder afgeronde curatieve antivirale behandeling of die bij de screening een virale belasting van HCV hebben die boven de kwantificeringsgrens ligt. Opmerking: deelnemers moeten de curatieve antivirale behandeling ten minste 4 weken vóór de inschrijving hebben afgerond","language":18,"languageDescription":"Dutch"},{"id":12576765,"uuid":"d9ec471b-b0ff-4280-80c7-c97a7f4ff499","attributeTranslation":"17. Uczestnicy ze stwierdzonym w wywiadzie zakażeniem wirusem zapalenia wątroby typu C (HCV), którzy nie ukończyli skutecznego leczenia przeciwwirusowego lub u których wiremia HCV pozostaje powyżej granicy oznaczalności podczas oceny przesiewowej. Uwaga: uczestnicy muszą ukończyć radykalne leczenie przeciwwirusowe co najmniej 4 tygodnie przed włączeniem do badania.","language":19,"languageDescription":"Polish"},{"id":12576764,"uuid":"d9ec471b-b0ff-4280-80c7-c97a7f4ff499","attributeTranslation":"17. Participantes con antecedentes conocidos de infección por el virus de la hepatitis C (VHC) que no hayan finalizado un tratamiento antivírico con intención curativa o cuya carga vírica del VHC sea superior al límite de cuantificación en la selección. Nota: Los participantes deben haber finalizado la terapia antivírica curativa al menos 4 semanas antes de la inclusión.","language":7,"languageDescription":"Spanish"}]},{"id":1717701,"number":18,"principalExclusionCriteria":"18. Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). HIV testing is not required unless mandated by local health authority.","principalExclusionCriteriaTranslations":[{"id":12576769,"uuid":"fa04c458-a149-4a5b-80b1-a0bbff47ec3f","attributeTranslation":"18. Stwierdzone w wywiadzie zakażenie ludzkim wirusem niedoboru odporności (HIV) (przeciwciała przeciwko wirusowi HIV 1/2). Badanie w kierunku zakażenia wirusem HIV nie jest obowiązkowe, chyba że jest wymagane przez lokalne organy ds. zdrowia.","language":19,"languageDescription":"Polish"},{"id":12576768,"uuid":"fa04c458-a149-4a5b-80b1-a0bbff47ec3f","attributeTranslation":"18. Een bekende voorgeschiedenis van infectie met humaan immunodeficiëntievirus (hiv) (hiv 1/2-antilichamen). Een hiv-test is niet vereist, tenzij dit verplicht is door de lokale gezondheidsautoriteit.","language":18,"languageDescription":"Dutch"},{"id":12576770,"uuid":"fa04c458-a149-4a5b-80b1-a0bbff47ec3f","attributeTranslation":"18. Antecedentes conocidos de infección por el virus de la inmunodeficiencia humana (VIH) (anticuerpos contra el VIH 1/2). No es necesario hacer una prueba de detección del VIH a menos que así lo exijan las autoridades sanitarias locales.","language":7,"languageDescription":"Spanish"},{"id":12576767,"uuid":"fa04c458-a149-4a5b-80b1-a0bbff47ec3f","attributeTranslation":"18. Antécédents connus d’infection par le virus de l’immunodéficience humaine (VIH) (anticorps anti-VIH-1/2). Le dépistage du VIH n’est pas requis, sauf si les autorités sanitaires locales l’exigent.","language":34,"languageDescription":"French (France)"}]},{"id":1717702,"number":19,"principalExclusionCriteria":"19. Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.","principalExclusionCriteriaTranslations":[{"id":12576771,"uuid":"a8b13499-4e16-4c79-829b-9bbb258f6878","attributeTranslation":"19. Antécédents de transplantation d’organe, y compris greffe de cellules souches autologues ou allogéniques, à l’exception des transplantations ne nécessitant pas d’immunosuppression.","language":34,"languageDescription":"French (France)"},{"id":12576773,"uuid":"a8b13499-4e16-4c79-829b-9bbb258f6878","attributeTranslation":"19. Stan po przeszczepieniu jakiegokolwiek narządu, w tym autologicznym i allogenicznym przeszczepieniu komórek macierzystych, z wyjątkiem przeszczepów niewymagających stosowania immunosupresji.","language":19,"languageDescription":"Polish"},{"id":12576774,"uuid":"a8b13499-4e16-4c79-829b-9bbb258f6878","attributeTranslation":"19. Ontvanger van een orgaantransplantaat, waaronder autologe en allogene stamceltransplantatie, met uitzondering van transplantaten waarvoor geen immuunsuppressie nodig is.","language":18,"languageDescription":"Dutch"},{"id":12576772,"uuid":"a8b13499-4e16-4c79-829b-9bbb258f6878","attributeTranslation":"19. Haber recibido cualquier tipo de trasplante de órgano, incluidos los alotrasplantes y autotrasplantes de células progenitoras, con la excepción de los trasplantes que no requieran inmunodepresores.","language":7,"languageDescription":"Spanish"}]},{"id":1717703,"number":2,"principalExclusionCriteria":"2. Disease suitable for local therapy administered with curative intent.","principalExclusionCriteriaTranslations":[{"id":12576777,"uuid":"93846bc5-4c34-4609-8fd2-e1b71f1c75e8","attributeTranslation":"2. Een aandoening die geschikt is voor lokale behandeling met curatieve intentie.","language":18,"languageDescription":"Dutch"},{"id":12576776,"uuid":"93846bc5-4c34-4609-8fd2-e1b71f1c75e8","attributeTranslation":"2. Maladie adaptée à un traitement local administré avec une visée curative.","language":34,"languageDescription":"French (France)"},{"id":12576775,"uuid":"93846bc5-4c34-4609-8fd2-e1b71f1c75e8","attributeTranslation":"2. Choroba kwalifikująca się do leczenia miejscowego prowadzonego z zamiarem wyleczenia.","language":19,"languageDescription":"Polish"},{"id":12576778,"uuid":"93846bc5-4c34-4609-8fd2-e1b71f1c75e8","attributeTranslation":"2. Enfermedad adecuada para una terapia local administrada con intención curativa.","language":7,"languageDescription":"Spanish"}]},{"id":1717704,"number":20,"principalExclusionCriteria":"20. Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to enrollment with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer defined as follows: Stage T1c or T2a with a Gleason score ≤6 and prostatic-specific antigen <10 ng/mL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to enrollment. Other exceptions may be considered with the Sponsor’s consultation. The time requirement for no malignancy for 2 years does not apply to cancer for which a participant is enrolled in the study","principalExclusionCriteriaTranslations":[{"id":12576782,"uuid":"f711b92d-0cdf-4d2b-859d-247d72acad64","attributeTranslation":"20. Rozpoznanie i/lub leczenie jakiegokolwiek innego dodatkowego nowotworu złośliwego w okresie 2 lat przed włączeniem do badania, z następującymi wyjątkami: skutecznie wyleczony rak podstawnokomórkowy lub płaskonabłonkowy skóry oraz wycięty radykalnie rak szyjki macicy in situ i wycięty radykalnie rak piersi in situ oraz rak gruczołu krokowego niskiego ryzyka we wczesnym stadium zaawansowania, zdefiniowany następująco: Stopień zaawansowania T1c lub T2a z wynikiem ≤6 w skali Gleasona i stężeniem swoistego antygenu sterczowego <10 ng/ml, poddany radykalnemu leczeniu lub nieleczony i poddany aktywnej obserwacji; stabilny stan choroby nowotworowej w okresie ostatniego roku przed włączeniem do badania. Inne wyjątki mogą zostać rozważone po konsultacji ze sponsorem. Wymóg czasowy niewystępowania nowotworu złośliwego w okresie 2 lat nie dotyczy nowotworu, z powodu którego uczestnik jest włączony do badania.","language":19,"languageDescription":"Polish"},{"id":12576780,"uuid":"f711b92d-0cdf-4d2b-859d-247d72acad64","attributeTranslation":"20. Pacientes a quienes se les ha diagnosticado o tratado cualquier otra neoplasia maligna adicional en los 2 años anteriores a la inclusión, con excepción de lo siguiente: carcinoma cutáneo basocelular o epidermoide tratado con intención curativa, y cáncer de cuello uterino y de mama in situ resecados con intención curativa; y cáncer de próstata en fase temprana de bajo riesgo, definida de la siguiente manera: estadio T1c o T2a con una puntuación en la escala de Gleason ≤6 y antígeno prostático específico <10 ng/ml que se haya tratado con intención definitiva o que no se haya tratado y esté bajo vigilancia activa que se haya mantenido estable durante el último año anterior a la inclusión. Se podrán considerar otras excepciones previa consulta con el Promotor. El requisito de que no se haya presentado ningún tipo de neoplasia maligna durante 2 años no se aplica a los tipos de cáncer por los que se incluya al participante en el estudio.","language":7,"languageDescription":"Spanish"},{"id":12576779,"uuid":"f711b92d-0cdf-4d2b-859d-247d72acad64","attributeTranslation":"20. Diagnostic et/ou traitement d’une autre tumeur maligne au cours des 2 années précédant l’inclusion, à l’exception des cas suivants : carcinome basocellulaire ou carcinome épidermoïde cutané ayant fait l’objet d’un traitement à visée curative, cancer du col de l’utérus in situ ayant fait l’objet d’une résection à visée curative, cancer du sein in situ ayant fait l’objet d’une résection à visée curative, et cancer de la prostate précoce à faible risque défini comme suit : Stade T1c ou T2a avec un score de Gleason ≤ 6 et un antigène prostatique spécifique (PSA) < 10 ng/ml, ayant fait l’objet d’un traitement à visée curative ou non traité, mais placé sous surveillance active et stable depuis l’année précédant l’inclusion. D’autres exceptions peuvent être envisagées après consultation du promoteur. L’exigence d’absence de tumeur maligne pendant 2 ans ne s’applique pas au cancer pour lequel le/la participant(e) est inclus(e) dans l’étude.","language":34,"languageDescription":"French (France)"},{"id":12576781,"uuid":"f711b92d-0cdf-4d2b-859d-247d72acad64","attributeTranslation":"20. Bekende diagnose van en/of behandeling voor een andere bijkomende maligniteit in de 2 jaar vóór inschrijving, met uitzondering van het volgende: curatief behandeld basaalcelcarcinoom of plaveiselcelcarcinoom van de huid, en curatief verwijderde baarmoederhalskanker in situ, en curatief verwijderde borstkanker in situ, en prostaatkanker in een vroeg stadium met een laag risico, gedefinieerd als volgt: stadium T1c of T2a met een Gleason-score ≤6 en een prostaatspecifiek antigeen <10 ng/ml, waarbij de patiënt ofwel met het oog op definitieve genezing is behandeld, ofwel onbehandeld is gebleven in het kader van actieve surveillance die het afgelopen jaar voorafgaand aan de inschrijving stabiel is gebleven. Andere uitzonderingen kunnen in overleg met de opdrachtgever in overweging worden genomen. De eis dat er gedurende 2 jaar geen sprake mag zijn geweest van een maligniteit, geldt niet voor kanker waarvoor een deelnemer in het onderzoek is ingeschreven","language":18,"languageDescription":"Dutch"}]},{"id":1717705,"number":21,"principalExclusionCriteria":"21. Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids. Corticosteroid use as premedication for allergic reactions (e.g., intravenous contrast), or as a prophylactic management of AEs related to the therapies specified in the protocol is allowed. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor","principalExclusionCriteriaTranslations":[{"id":12576786,"uuid":"9dafef0a-1518-401f-a322-c468f170700e","attributeTranslation":"21. Cualquier afección que requiera un tratamiento sistémico con corticosteroides (>10 mg diarios de prednisona o equivalente) u otros inmunodepresores en los 7 días previos a la primera dosis del tratamiento del estudio, salvo los corticosteroides de uso tópico, intranasal, intrabronquial u ocular. Se permite el uso de corticoesteroides como premedicación para las reacciones alérgicas (p. ej., contraste intravenoso) o como tratamiento profiláctico de los AA relacionados con los tratamientos especificados en el protocolo. El uso de dosis fisiológicas de corticoesteroides podrá autorizarse previa consulta con el Promotor.","language":7,"languageDescription":"Spanish"},{"id":12576784,"uuid":"9dafef0a-1518-401f-a322-c468f170700e","attributeTranslation":"21. Toute affection nécessitant un traitement systémique par corticoïdes (> 10 mg/jour de prednisone ou équivalent) ou par tout autre médicament immunosuppresseur au cours des 7 jours précédant l’administration de la première dose du traitement à l’étude, à l’exception des corticoïdes topiques, intranasaux, intrabronchiques ou ophtalmiques. L’utilisation de corticoïdes comme prémédication en cas de réactions allergiques (p. ex. lors de l’administration d’un produit de contraste par voie intraveineuse) ou à titre prophylactique pour la prise en charge des EI liés aux traitements spécifiés dans le protocole est autorisée. L’utilisation de doses physiologiques de corticoïdes peut être approuvée après consultation du promoteur.","language":34,"languageDescription":"French (France)"},{"id":12576783,"uuid":"9dafef0a-1518-401f-a322-c468f170700e","attributeTranslation":"21. Jakikolwiek stan medyczny wymagający ogólnoustrojowego leczenia kortykosteroidami (w dawce równoważnej >10 mg prednizonu na dobę) bądź innymi lekami immunosupresyjnymi w okresie 7 dni przed otrzymaniem pierwszej dawki badanego leczenia, z wyjątkiem kortykosteroidów stosowanych miejscowo, donosowo, dooskrzelowo lub do oka. Dozwolone jest stosowanie kortykosteroidów w ramach premedykacji w przypadku reakcji alergicznych (np. na dożylny środek kontrastowy) lub w ramach profilaktyki AE związanych z terapiami opisanymi w protokole. Stosowanie fizjologicznych dawek kortykosteroidów może zostać zatwierdzone po konsultacji ze sponsorem.","language":19,"languageDescription":"Polish"},{"id":12576785,"uuid":"9dafef0a-1518-401f-a322-c468f170700e","attributeTranslation":"21. Elke aandoening waarvoor systemische behandeling met corticosteroïden (>10 mg prednison of equivalent per dag) of andere immunosuppressieve medicatie nodig is binnen 7 dagen voorafgaand aan de eerste dosis onderzoeksbehandeling, met uitzondering van lokaal, intranasaal, intrabronchiaal of oculair toegediende corticosteroïden. Het gebruik van corticosteroïden als premedicatie bij allergische reacties (bijvoorbeeld bij intraveneus contrastmiddel) of als profylactisch beheer van bijwerkingen die verband houden met de in het protocol gespecificeerde behandelingen is toegestaan. Het gebruik van fysiologische doses corticosteroïden kan worden goedgekeurd na overleg met de opdrachtgever","language":18,"languageDescription":"Dutch"}]},{"id":1717706,"number":22,"principalExclusionCriteria":"22. Use of a live or live attenuated vaccine within 4 weeks prior to Screening. Note: Administration of killed, recombinant or inactivated vaccines is allowed.","principalExclusionCriteriaTranslations":[{"id":12576790,"uuid":"0dbfa92e-5abf-4a7b-8c23-a791ab46a44f","attributeTranslation":"22. Het gebruik van een levend of verzwakt levend vaccin binnen 4 weken voorafgaand aan de screening. Opmerking: Het toedienen van gedode, recombinante of geïnactiveerde vaccins is toegestaan.","language":18,"languageDescription":"Dutch"},{"id":12576788,"uuid":"0dbfa92e-5abf-4a7b-8c23-a791ab46a44f","attributeTranslation":"22. Administration d’un vaccin vivant ou vivant atténué au cours des 4 semaines précédant la sélection. Remarque : l’administration de vaccins tués, recombinants ou inactivés est autorisée.","language":34,"languageDescription":"French (France)"},{"id":12576789,"uuid":"0dbfa92e-5abf-4a7b-8c23-a791ab46a44f","attributeTranslation":"22. Zastosowanie żywej lub żywej atenuowanej szczepionki w okresie 4 tygodni przed oceną przesiewową. Uwaga: Dozwolone jest podawanie szczepionek zawierających zabite, rekombinowane lub inaktywowane mikroorganizmy.","language":19,"languageDescription":"Polish"},{"id":12576787,"uuid":"0dbfa92e-5abf-4a7b-8c23-a791ab46a44f","attributeTranslation":"22. Uso de una vacuna elaborada con microbios vivos o de virulencia atenuada en las 4 semanas anteriores a la selección. Nota: Se permite la administración de vacunas de virulencia inactivada, recombinantes o elaboradas con microbios muertos.","language":7,"languageDescription":"Spanish"}]},{"id":1717707,"number":23,"principalExclusionCriteria":"23. Active pregnancy or breastfeeding.","principalExclusionCriteriaTranslations":[{"id":12576792,"uuid":"b156c192-9f27-4e48-bc04-420866a57549","attributeTranslation":"23. Aktualna ciąża lub karmienie piersią.","language":19,"languageDescription":"Polish"},{"id":12576793,"uuid":"b156c192-9f27-4e48-bc04-420866a57549","attributeTranslation":"23. Actieve zwangerschap of geven van borstvoeding.","language":18,"languageDescription":"Dutch"},{"id":12576794,"uuid":"b156c192-9f27-4e48-bc04-420866a57549","attributeTranslation":"23. Embarazo en curso o periodo de lactancia.","language":7,"languageDescription":"Spanish"},{"id":12576791,"uuid":"b156c192-9f27-4e48-bc04-420866a57549","attributeTranslation":"23. Grossesse ou allaitement en cours.","language":34,"languageDescription":"French (France)"}]},{"id":1717708,"number":24,"principalExclusionCriteria":"24. History of (noninfectious) pneumonitis/interstitial lung disease or has current pneumonitis/interstitial lung disease.","principalExclusionCriteriaTranslations":[{"id":12576797,"uuid":"1d31db91-939a-4a70-9d98-7c795c670f9b","attributeTranslation":"24. Antécédents de pneumopathie inflammatoire (non infectieuse)/pneumopathie interstitielle diffuse ou pneumopathie inflammatoire/pneumopathie interstitielle diffuse en cours.","language":34,"languageDescription":"French (France)"},{"id":12576798,"uuid":"1d31db91-939a-4a70-9d98-7c795c670f9b","attributeTranslation":"24. Antecedentes de neumonitis o neumopatía intersticial (no infecciosas), o neumonitis o neumopatía intersticial actual.","language":7,"languageDescription":"Spanish"},{"id":12576795,"uuid":"1d31db91-939a-4a70-9d98-7c795c670f9b","attributeTranslation":"24. Een voorgeschiedenis van (niet-infectieuze) pneumonitis/interstitiële longziekte of lijdt momenteel aan pneumonitis/interstitiële longziekte.","language":18,"languageDescription":"Dutch"},{"id":12576796,"uuid":"1d31db91-939a-4a70-9d98-7c795c670f9b","attributeTranslation":"24. (Niezakaźne) zapalenie płuc/śródmiąższowa choroba płuc w wywiadzie lub zapalenie płuc/śródmiąższowa choroba płuc w chwili obecnej.","language":19,"languageDescription":"Polish"}]},{"id":1717709,"number":25,"principalExclusionCriteria":"25. History of any of the following drug-induced severe cutaneous adverse reactions including, but not limited to, Stevens Johnson syndrome/toxic epidermal necrolysis, or drug-reaction with eosinophilia and systemic symptoms, or dose-limiting immune-mediated reactions","principalExclusionCriteriaTranslations":[{"id":12576801,"uuid":"9882c203-3f81-4906-adc7-2c4544ba21d6","attributeTranslation":"25. Stwierdzone w wywiadzie którekolwiek z następujących polekowych ciężkich skórnych działań niepożądanych (między innymi): zespół Stevensa‑Johnsona/toksyczna nekroliza naskórka, reakcja polekowa z eozynofilią i objawami ogólnymi lub reakcje immunologiczne ograniczające dawkę","language":19,"languageDescription":"Polish"},{"id":12576802,"uuid":"9882c203-3f81-4906-adc7-2c4544ba21d6","attributeTranslation":"25. Antecedentes de cualquiera de las siguientes reacciones adversas cutáneas graves inducidas por fármacos, entre las que se incluyen, entre otras, el síndrome de Stevens-Johnson o la necrólisis epidérmica tóxica, la reacción farmacológica con eosinofilia y síntomas sistémicos o reacciones inmunomediadas limitantes de la dosis.","language":7,"languageDescription":"Spanish"},{"id":12576800,"uuid":"9882c203-3f81-4906-adc7-2c4544ba21d6","attributeTranslation":"25. Antécédents de l’une des réactions cutanées indésirables sévères induites par un médicament suivantes, mais sans s’y limiter, syndrome de Stevens-Johnson/nécrolyse épidermique toxique, réaction médicamenteuse avec éosinophilie et symptômes systémiques (DRESS), ou réactions à médiation immunitaire limitant la dose.","language":34,"languageDescription":"French (France)"},{"id":12576799,"uuid":"9882c203-3f81-4906-adc7-2c4544ba21d6","attributeTranslation":"25. Een voorgeschiedenis van een van de volgende ernstige, door geneesmiddelen geïnduceerde bijwerkingen van de huid, waaronder, maar niet beperkt tot, Stevens-Johnson-syndroom/toxische epidermale necrolyse, of een geneesmiddelreactie met eosinofilie en systemische symptomen, of dosisbeperkende immuungemedieerde reacties","language":18,"languageDescription":"Dutch"}]},{"id":1717710,"number":3,"principalExclusionCriteria":"3. Prior treatment with anti-transforming growth factor-beta (TGF-β) therapy.","principalExclusionCriteriaTranslations":[{"id":12576805,"uuid":"6aa4203b-ee4c-4f15-a93a-ec0fb77dbd5d","attributeTranslation":"3. Eerdere behandeling met een therapie gericht tegen de transformerende groeifactor-bèta (TGF-β).","language":18,"languageDescription":"Dutch"},{"id":12576804,"uuid":"6aa4203b-ee4c-4f15-a93a-ec0fb77dbd5d","attributeTranslation":"3. Traitement antérieur par une thérapie anti-facteur de croissance transformant bêta (TGF-β).","language":34,"languageDescription":"French (France)"},{"id":12576806,"uuid":"6aa4203b-ee4c-4f15-a93a-ec0fb77dbd5d","attributeTranslation":"3. Wcześniejsze leczenie inhibitorem transformującego czynnika wzrostu beta (TGF‑β).","language":19,"languageDescription":"Polish"},{"id":12576803,"uuid":"6aa4203b-ee4c-4f15-a93a-ec0fb77dbd5d","attributeTranslation":"3. Tratamiento anterior con terapia contra el factor de crecimiento y transformación β (FCT-β).","language":7,"languageDescription":"Spanish"}]},{"id":1717711,"number":4,"principalExclusionCriteria":"4. Prior therapy with an anti-EGFR antibody","principalExclusionCriteriaTranslations":[{"id":12576808,"uuid":"3597df62-7ba4-48b7-9b7e-23c8b5d0c568","attributeTranslation":"4. Wcześniejsze leczenie przeciwciałem anty‑EGFR","language":19,"languageDescription":"Polish"},{"id":12576809,"uuid":"3597df62-7ba4-48b7-9b7e-23c8b5d0c568","attributeTranslation":"4. Traitement antérieur par un anticorps anti-EGFR","language":34,"languageDescription":"French (France)"},{"id":12576807,"uuid":"3597df62-7ba4-48b7-9b7e-23c8b5d0c568","attributeTranslation":"4. Eerdere behandeling met anti EGFR-antilichaam","language":18,"languageDescription":"Dutch"},{"id":12576810,"uuid":"3597df62-7ba4-48b7-9b7e-23c8b5d0c568","attributeTranslation":"4. Terapia anterior con un anticuerpo anti-EGFR.","language":7,"languageDescription":"Spanish"}]},{"id":1717712,"number":5,"principalExclusionCriteria":"5. Prior (neoadjuvant and/or adjuvant) therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.","principalExclusionCriteriaTranslations":[{"id":12576814,"uuid":"7938442d-28e8-42f0-a834-10c42c5c8ec8","attributeTranslation":"5. Terapia previa (neoadyuvante o adyuvante) con un inhibidor de los puntos de control inmunitario finalizado en los 6 meses anteriores al inicio del tratamiento del estudio.","language":7,"languageDescription":"Spanish"},{"id":12576811,"uuid":"7938442d-28e8-42f0-a834-10c42c5c8ec8","attributeTranslation":"5. Eerdere (neoadjuvante en/of adjuvante) behandeling met een immuuncheckpointremmer die binnen 6 maanden voorafgaand aan de start van de onderzoeksbehandeling is afgerond.","language":18,"languageDescription":"Dutch"},{"id":12576812,"uuid":"7938442d-28e8-42f0-a834-10c42c5c8ec8","attributeTranslation":"5. Traitement antérieur (néoadjuvant et/ou adjuvant) par un inhibiteur de point de contrôle immunitaire terminé au cours des 6 mois précédant l’instauration du traitement à l’étude.","language":34,"languageDescription":"French (France)"},{"id":12576813,"uuid":"7938442d-28e8-42f0-a834-10c42c5c8ec8","attributeTranslation":"5. Wcześniejsze (neoadiuwantowe i/lub adiuwantowe) leczenie inhibitorem immunologicznego punktu kontrolnego zakończone w okresie 6 miesięcy przed rozpoczęciem badanego leczenia.","language":19,"languageDescription":"Polish"}]},{"id":1717713,"number":6,"principalExclusionCriteria":"6. PD (radiologically or pathologically confirmed) <6 months from completion of curative intent platinum-containing systemic therapy for locoregionally advanced HNSCC.","principalExclusionCriteriaTranslations":[{"id":12576815,"uuid":"82f212fa-af4a-4589-903b-7ce02a6371b4","attributeTranslation":"6. PD (potwierdzona radiologicznie lub histopatologicznie) <6 miesięcy po zakończeniu terapii ogólnoustrojowej z zamiarem wyleczenia opartej na pochodnych platyny z powodu lokoregionalnie zaawansowanego HNSCC.","language":19,"languageDescription":"Polish"},{"id":12576818,"uuid":"82f212fa-af4a-4589-903b-7ce02a6371b4","attributeTranslation":"6. PE (confirmada radiológica o patológicamente) <6 meses desde la finalización de la terapia sistémica con derivados del platino con intención curativa para el CECC locorregionalmente avanzado.","language":7,"languageDescription":"Spanish"},{"id":12576816,"uuid":"82f212fa-af4a-4589-903b-7ce02a6371b4","attributeTranslation":"6. PD (radiologisch of pathologisch bevestigd) <6 maanden na afronding van een platina bevattende systemische therapie met curatieve intentie voor locoregionaal gevorderd HNSCC.","language":18,"languageDescription":"Dutch"},{"id":12576817,"uuid":"82f212fa-af4a-4589-903b-7ce02a6371b4","attributeTranslation":"6. MP (confirmée radiologiquement ou par un examen anatomo-pathologique) survenant moins de 6 mois après la fin d’un traitement systémique à base de platine administré avec une visée curative pour un CETC localement avancé avec extension régionale.","language":34,"languageDescription":"French (France)"}]},{"id":1717714,"number":7,"principalExclusionCriteria":"7. Life expectancy of less than 3 months and/or has rapidly progressing disease in the treating investigator's opinion.","principalExclusionCriteriaTranslations":[{"id":12576821,"uuid":"d2ceaf89-82d6-4b08-b7bb-83cd6c0b6fcf","attributeTranslation":"7. Een verwachte levensduur van minder dan 3 maanden en/of een naar het oordeel van de behandelend onderzoeker snel voortschrijdende ziekte.","language":18,"languageDescription":"Dutch"},{"id":12576819,"uuid":"d2ceaf89-82d6-4b08-b7bb-83cd6c0b6fcf","attributeTranslation":"7. Esperanza de vida inferior a 3 meses o enfermedad que progresa rápidamente a juicio del investigador responsable del tratamiento.","language":7,"languageDescription":"Spanish"},{"id":12576822,"uuid":"d2ceaf89-82d6-4b08-b7bb-83cd6c0b6fcf","attributeTranslation":"7. Przewidywany czas przeżycia krótszy niż 3 miesiące i/lub szybko postępująca choroba w opinii badacza prowadzącego leczenie.","language":19,"languageDescription":"Polish"},{"id":12576820,"uuid":"d2ceaf89-82d6-4b08-b7bb-83cd6c0b6fcf","attributeTranslation":"7. Espérance de vie inférieure à 3 mois et/ou maladie à progression rapide selon l’avis de l’investigateur traitant.","language":34,"languageDescription":"French (France)"}]},{"id":1717715,"number":8,"principalExclusionCriteria":"8. Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, and leptomeningeal disease are excluded. Participants with a history of treated central nervous system metastases (by surgery or radiation therapy) may be eligible if central nervous system metastases have been stable for at least 4 weeks, i.e., without evidence of progression by repeat imaging and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.","principalExclusionCriteriaTranslations":[{"id":12576824,"uuid":"89a31ec7-55fa-4c46-b21f-2626287fe0ee","attributeTranslation":"8. Se excluyen las metástasis activas conocidas en el sistema nervioso central, los antecedentes de compresión de la médula espinal debida a afectación tumoral, los antecedentes de meningitis carcinomatosa y la metástasis leptomeníngea. Los participantes con antecedentes de metástasis en el sistema nervioso central tratadas (mediante cirugía o radioterapia) podrán ser elegibles si dichas metástasis se han mantenido estables durante al menos 4 semanas, es decir, sin signos de progresión en las pruebas de diagnóstico por la imagen repetidas y sin necesidad de tratamiento con corticoesteroides durante al menos 14 días antes de la primera dosis del tratamiento del estudio.","language":7,"languageDescription":"Spanish"},{"id":12576825,"uuid":"89a31ec7-55fa-4c46-b21f-2626287fe0ee","attributeTranslation":"8. Bekende actieve uitzaaiingen in het centrale zenuwstelsel, een voorgeschiedenis van ruggenmergcompressie als gevolg van tumorbetrokkenheid, een voorgeschiedenis van carcinomateuze meningitis en leptomeningeale aandoeningen worden uitgesloten. Deelnemers met een voorgeschiedenis van behandelde metastasen in het centrale zenuwstelsel (door operatie of bestralingstherapie) kunnen in aanmerking komen indien de uitzaaiingen in het centrale zenuwstelsel gedurende ten minste 4 weken stabiel zijn gebleven, d.w.z. zonder aanwijzingen voor progressie bij herhaalde beeldvorming en zonder dat er gedurende ten minste 14 dagen voorafgaand aan de eerste dosis van de onderzoeksbehandeling een behandeling met steroïden nodig was.","language":18,"languageDescription":"Dutch"},{"id":12576823,"uuid":"89a31ec7-55fa-4c46-b21f-2626287fe0ee","attributeTranslation":"8. Stwierdzone aktywne przerzuty do ośrodkowego układu nerwowego, ucisk rdzenia kręgowego w wywiadzie związany z obecnością guza, nowotworowe zapalenie opon mózgowo‑rdzeniowych w wywiadzie oraz zajęcie opon miękkich stanowią wykluczenie. Uczestnicy z leczonymi (chirurgicznie lub radioterapią) przerzutami do ośrodkowego układu nerwowego w wywiadzie mogą kwalifikować się do badania, jeśli przerzuty do ośrodkowego układu nerwowego pozostawały stabilne od co najmniej 4 tygodni, tj. bez oznak progresji choroby w powtarzanych badaniach obrazowych i bez konieczności stosowania steroidoterapii przez co najmniej 14 dni przed podaniem pierwszej dawki badanego leczenia.","language":19,"languageDescription":"Polish"},{"id":12576826,"uuid":"89a31ec7-55fa-4c46-b21f-2626287fe0ee","attributeTranslation":"8. Les participants présentant des métastases actives connues du système nerveux central, des antécédents de compression médullaire due à une atteinte tumorale, des antécédents de méningite carcinomateuse ou une atteinte leptoméningée sont exclus. Les participants ayant des antécédents de métastases du système nerveux central traitées (par chirurgie ou radiothérapie) peuvent être éligibles si ces métastases sont stables depuis au moins 4 semaines, c.-à-d. sans signe de progression sur les examens d’imagerie de contrôle et sans qu’un traitement par corticoïdes n’ait été nécessaire au moins 14 jours avant l’administration de la première dose du traitement à l’étude.","language":34,"languageDescription":"French (France)"}]},{"id":1717716,"number":9,"principalExclusionCriteria":"9. Participants who are at higher risk of bleeding, including participants with known bleeding diathesis, or who have current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.  A major bleeding episode is defined according to the International Society on Thrombosis and Haemostasis criteria, which include fatal bleeding, symptomatic bleeding in a critical organ/area (e.g., intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal), hemoglobin drop ≥2 g/dL, or transfusion of ≥2 units of blood. Cases of tumor-related bleeding within the last 4 weeks, or other risk factors potentially increasing the risk of bleeding, should be discussed with the Sponsor Medical Director prior to enrollment.","principalExclusionCriteriaTranslations":[{"id":12576827,"uuid":"59700d98-8c5d-4858-b595-176a79b93233","attributeTranslation":"9. Les participants présentant un risque accru d’hémorragie, notamment ceux présentant une diathèse hémorragique connue, une hémorragie majeure active ou un épisode hémorragique majeur survenu au cours des 4 semaines précédant l’inclusion. \nUn épisode hémorragique majeur est défini conformément aux critères de l’International Society on Thrombosis and Haemostasis ; il comprend les hémorragies fatales, les hémorragies symptomatiques touchant un organe ou une zone critique (p. ex. intracrânienne, intrarachidienne, intraoculaire, péricardique, intra-articulaire, intramusculaire avec syndrome des loges ou rétropéritonéale), une baisse du taux d’hémoglobine ≥ 2 g/dl ou la transfusion de ≥ 2 unités de sang.\nLes cas d’hémorragie liée à la tumeur survenus au cours des 4 dernières semaines, ainsi que les autres facteurs de risque susceptibles d’augmenter le risque hémorragique, devront être discutés avec le directeur médical du promoteur avant l’inclusion.","language":34,"languageDescription":"French (France)"},{"id":12576828,"uuid":"59700d98-8c5d-4858-b595-176a79b93233","attributeTranslation":"9. Deelnemers die een verhoogd risico op bloedingen lopen, waaronder deelnemers met een bekende bloedingsdiathese, of die momenteel een actieve ernstige bloeding hebben, of die binnen 4 weken voorafgaand aan de inschrijving een ernstige bloeding hebben gehad. \nEen ernstige bloeding wordt gedefinieerd volgens de criteria van de International Society on Thrombosis and Haemostasis, waaronder fatale bloedingen, symptomatische bloedingen in een vitaal orgaan of gebied (bijvoorbeeld intracraniaal, intraspinaal, intraoculair, pericardiaal, intra-articulair, intramusculair met compartimentsyndroom, retroperitoneaal), een daling van het hemoglobinegehalte met ≥2 g/dl, of een transfusie van ≥2 eenheden bloed.\nGevallen van tumorgerelateerde bloedingen in de afgelopen 4 weken, of andere risicofactoren die het risico op bloedingen mogelijk vergroten, dienen vóór de inschrijving te worden besproken met de medisch directeur van de opdrachtgever.","language":18,"languageDescription":"Dutch"},{"id":12576830,"uuid":"59700d98-8c5d-4858-b595-176a79b93233","attributeTranslation":"9. Uczestnicy z grupy podwyższonego ryzyka krwawienia, w tym uczestnicy ze stwierdzoną skazą krwotoczną lub z aktualnym aktywnym poważnym krwawieniem bądź z niedawno przebytym poważnym epizodem krwawienia w okresie 4 tygodni przed włączeniem do badania. Epizod poważnego krwawienia zdefiniowano zgodnie z kryteriami Międzynarodowego Towarzystwa Zakrzepicy i Hemostazy, które obejmują krwawienie prowadzące do zgonu, objawowe krwawienie w obrębie ważnego narządu/obszaru (np. wewnątrzczaszkowe, do rdzenia kręgowego, wewnątrzgałkowe, osierdziowe, dostawowe, domięśniowe z zespołem ciasnoty przedziałów powięziowych, zaotrzewnowe), spadek stężenia hemoglobiny o ≥2 g/dl lub przetoczenie ≥2 jednostek krwi.\nPrzypadki krwawienia związanego z guzem w okresie ostatnich 4 tygodni lub inne czynniki ryzyka potencjalnie zwiększające ryzyko krwawienia należy omówić z Dyrektorem Medycznym Sponsora przed włączeniem pacjenta do badania.","language":19,"languageDescription":"Polish"},{"id":12576829,"uuid":"59700d98-8c5d-4858-b595-176a79b93233","attributeTranslation":"9. Participantes con mayor riesgo de hemorragia, incluidos aquellos con diátesis hemorrágica conocida, o que presenten una hemorragia grave activa en la actualidad, o que hayan sufrido un episodio de hemorragia grave en las 4 semanas anteriores a la inclusión.\nLos episodios de hemorragia grave se definen según los criterios de la Sociedad Internacional de Trombosis y Hemostasia, que incluyen hemorragias mortales, hemorragias sintomáticas en un órgano o zona críticos (p. ej., intracraneales, intrarraquídeas, intraoculares, pericárdicas, intraarticulares, intramusculares con síndrome compartimental o retroperitoneales), una disminución de la hemoglobina ≥2 g/dl o una transfusión de ≥2 unidades de sangre.\nLos casos de hemorragia relacionada con un tumor en las últimas 4 semanas, u otros factores de riesgo que puedan aumentar el riesgo de hemorragia, deben comentarse con el director médico del Promotor antes de la inclusión.","language":7,"languageDescription":"Spanish"}]}]},"endPoint":{"primaryEndPoints":[{"id":1176934,"number":1,"endPoint":"Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors 1.1 and alive after randomization","isPrimary":true,"endPointTranslations":[{"id":12576710,"uuid":"1b2e16e6-2d64-4914-91ff-3fad6e5af365","attributeTranslation":"Odsetek uczestników w fazie leczenia podtrzymującego, u których nie wystąpiła progresja choroby według zaślepionej niezależnej oceny centralnej zgodnie z kryteriami oceny odpowiedzi w guzach litych w wersji 1.1 i którzy pozostają przy życiu po randomizacji","language":19,"languageDescription":"Polish"},{"id":12576707,"uuid":"1b2e16e6-2d64-4914-91ff-3fad6e5af365","attributeTranslation":"Het percentage deelnemers in de onderhoudsfase dat progressievrij is, zoals beoordeeld door een geblindeerde onafhankelijke centrale beoordeling (BICR) volgens Response Evaluation Criteria in Solid Tumors, v1.1 (RECIST v1.1) en leeft na randomisatie","language":18,"languageDescription":"Dutch"},{"id":12576709,"uuid":"1b2e16e6-2d64-4914-91ff-3fad6e5af365","attributeTranslation":"Porcentaje de participantes en la fase de mantenimiento que no presentan progresión de la enfermedad, según una evaluación central independiente con enmascaramiento, de acuerdo con los Criterios de evaluación de la respuesta en tumores sólidos 1.1, y que siguen con vida tras la aleatorización.","language":7,"languageDescription":"Spanish"},{"id":12576708,"uuid":"1b2e16e6-2d64-4914-91ff-3fad6e5af365","attributeTranslation":"Proportion de participants en phase d’entretien qui sont en vie et ne présentent aucune progression après la randomisation, selon l’évaluation réalisée par une revue centrale indépendante en aveugle conformément aux critères d’évaluation de la réponse dans les tumeurs solides version 1.1.","language":34,"languageDescription":"French (France)"}]}],"secondaryEndPoints":[{"id":1176935,"number":1,"endPoint":"1. Observed predose and 0.5 h post-end-of-infusion concentrations of ficerafusp alfa Model-predicted AUC for Cycle x and Cycle x of ficerafusp alfa","isPrimary":false,"endPointTranslations":[{"id":12576711,"uuid":"6cee2734-8a79-456c-a131-7e71821ae61a","attributeTranslation":"1. \"Zaobserwowane przed podaniem badanego leku oraz 0,5 h po zakończeniu wlewu stężenia ficerafuspu alfa Przewidywana na podstawie modelu wartość AUC dla cyklu x i cyklu x leczenia ficerafuspem alfa","language":19,"languageDescription":"Polish"},{"id":12576714,"uuid":"6cee2734-8a79-456c-a131-7e71821ae61a","attributeTranslation":"1. Concentrations de ficerafusp alfa observées avant la perfusion et 0,5 heure après la fin de la perfusion.\nASC prévue par le modèle pour les cycles x et x du ficerafusp alfa.","language":34,"languageDescription":"French (France)"},{"id":12576712,"uuid":"6cee2734-8a79-456c-a131-7e71821ae61a","attributeTranslation":"1. Concentraciones observadas de ficerafusp alfa antes de la dosis y 0,5 h después del final de la infusión.\nAUC prevista por el modelo para el Ciclo X y Ciclo X de ficerafusp alfa.","language":7,"languageDescription":"Spanish"},{"id":12576713,"uuid":"6cee2734-8a79-456c-a131-7e71821ae61a","attributeTranslation":"1. Gemeten concentraties van ficerafusp alfa vóór toediening en 0,5 uur na het einde van de infusie; door het model voorspelde AUC voor cyclus x en cyclus x van ficerafusp alfa","language":18,"languageDescription":"Dutch"}]},{"id":1176936,"number":2,"endPoint":"2. *Assessed by BICR per RECIST 1.1: Objective response rate (ORR); Disease control rate (DCR); Clinical benefit rate (CBR); Duration of response (DOR);  Progression-free survival (PFS). *Overall Survival (OS).","isPrimary":false,"endPointTranslations":[{"id":12576717,"uuid":"fb95b00a-6ada-462c-b2f5-b47e7ae0446c","attributeTranslation":"2. *Beoordeeld door BICR volgens RECIST v1.1: Objectief responspercentage (ORR); Ziektebeheersingspercentage (DCR); Percentage klinisch voordeel (CBR); Duur van de respons (DOR); Progressievrije overleving (PFS). *Totale overleving (OS).","language":18,"languageDescription":"Dutch"},{"id":12576715,"uuid":"fb95b00a-6ada-462c-b2f5-b47e7ae0446c","attributeTranslation":"2. *W ocenie BICR zgodnie z kryteriami RECIST 1.1: Odsetek odpowiedzi obiektywnych (ORR); wskaźnik kontroli choroby (DCR); wskaźnik korzyści klinicznych (CBR); czas trwania odpowiedzi (DOR); czas przeżycia bez progresji choroby (PFS). *Całkowity czas przeżycia (OS).","language":19,"languageDescription":"Polish"},{"id":12576718,"uuid":"fb95b00a-6ada-462c-b2f5-b47e7ae0446c","attributeTranslation":"2. * Con arreglo a la ECIE según RECIST 1.1.: tasa de respuesta objetiva (TRO); tasa de control de la enfermedad (TCE); tasa de beneficio clínico (TBC); duración de la respuesta (DdR); supervivencia sin progresión (SSP). * Supervivencia global (SG).","language":7,"languageDescription":"Spanish"},{"id":12576716,"uuid":"fb95b00a-6ada-462c-b2f5-b47e7ae0446c","attributeTranslation":"2. *Évaluation par la RCIA selon les critères RECIST 1.1 : Taux de réponse objective (TRO) ; taux de contrôle de la maladie (TCM) ; taux de bénéfice clinique (TBC) ; durée de la réponse (DR) ; survie sans progression (SSP). *Survie globale (SG).","language":34,"languageDescription":"French (France)"}]},{"id":1176937,"number":3,"endPoint":"3. *Assessed by BICR per RECIST 1.1: ORR;  DCR; DOR; Time to first response (TTR); Deep response rate among responders (defined as best target lesion shrinkage ≥80%); Time (weeks) to maximum tumor shrinkage among responders; Time (weeks) to maximum tumor shrinkage;  PFS.*OS","isPrimary":false,"endPointTranslations":[{"id":12576719,"uuid":"4b9800e5-4783-4550-b984-425df1ab8145","attributeTranslation":"3. * Con arreglo a la ECIE según RECIST 1.1.: TRO; TCE; DdR; tiempo hasta la respuesta (TR); tasa de respuesta profunda entre los pacientes que respondieron al tratamiento (definida como mejor reducción de la lesión diana ≥80 %); tiempo (semanas) hasta la reducción tumoral máxima entre los pacientes que respondieron al tratamiento; tiempo (semanas) hasta la reducción tumoral máxima; SSP. * SG.","language":7,"languageDescription":"Spanish"},{"id":12576722,"uuid":"4b9800e5-4783-4550-b984-425df1ab8145","attributeTranslation":"3. *Beoordeeld door BICR volgens RECIST v1.1: ORR; DCR; DOR; Tijd tot eerste respons (TTR); Percentage diepe respons bij responders (gedefinieerd als beste afname van de doellaesie met ≥80%); Tijd (weken) tot maximale tumorafname bij responders; Tijd (weken) tot maximale tumorafname; PFS.*OS","language":18,"languageDescription":"Dutch"},{"id":12576721,"uuid":"4b9800e5-4783-4550-b984-425df1ab8145","attributeTranslation":"3. *W ocenie BICR zgodnie z kryteriami RECIST 1.1: ORR; DCR; DOR; Czas do pierwszej odpowiedzi (TTR); Odsetek głębokich odpowiedzi wśród pacjentów z odpowiedzią (zdefiniowaną jako największe zmniejszenie ocenianej zmiany o ≥80%); Czas (w tygodniach) do maksymalnego zmniejszenia guza wśród pacjentów z odpowiedzią; Czas (w tygodniach) do maksymalnego zmniejszenia guza; PFS. *OS","language":19,"languageDescription":"Polish"},{"id":12576720,"uuid":"4b9800e5-4783-4550-b984-425df1ab8145","attributeTranslation":"3. *Évaluation par la RCIA selon les critères RECIST 1.1 : TRO ; TCM ; DR ; délai jusqu’à la première réponse (TTR) ; taux de réponse profonde chez les patients répondeurs (définie comme une réduction maximale ≥ 80 % de la lésion cible) ; délai (en semaines) jusqu’à la réduction maximale de la tumeur chez les patients répondeurs ; délai (en semaines) jusqu’à la réduction maximale de la tumeur ; SSP. *SG","language":34,"languageDescription":"French (France)"}]},{"id":1176938,"number":4,"endPoint":"4. *Incidence, severity, and type of treatmentemergent adverse events (TEAEs). *Incidence of ≥Grade 3 TEAEs. *Serious adverse events (SAEs). *Adverse events (AEs) leading to dose modifications (dose reduction, interruption, dose held, or discontinuation). *Clinical laboratory abnormalities.","isPrimary":false,"endPointTranslations":[{"id":12576726,"uuid":"bea9ff79-f770-4cec-a400-5a4cbdb2fc8b","attributeTranslation":"4. *Częstość występowania, stopień nasilenia i rodzaj zdarzeń niepożądanych zaobserwowanych po zastosowaniu leczenia (TEAE). *Częstość występowania TEAE stopnia ≥3. *Ciężkie zdarzenia niepożądane (SAE). *Zdarzenia niepożądane (AE) prowadzące do modyfikacji dawki (zmniejszenia dawki, wstrzymania leczenia, odroczenia dawki lub przerwania leczenia). *Nieprawidłowości w badaniach laboratoryjnych.","language":19,"languageDescription":"Polish"},{"id":12576725,"uuid":"bea9ff79-f770-4cec-a400-5a4cbdb2fc8b","attributeTranslation":"4. * Incidencia, gravedad y tipo de tratamiento; acontecimientos adversos surgidos durante el tratamiento (AAST). * Incidencia de AAST de grado ≥3. * Acontecimientos adversos graves (AAG). * Acontecimientos adversos (AA) que dan lugar a modificaciones de la dosis (reducción de la dosis, interrupción, retención de la dosis o suspensión). * Anomalías analíticas.","language":7,"languageDescription":"Spanish"},{"id":12576723,"uuid":"bea9ff79-f770-4cec-a400-5a4cbdb2fc8b","attributeTranslation":"4. *Incidentie, ernst en aard van tijdens de behandeling optredende bijwerkingen (TEAE’s). *Incidentie van TEAE’s van graad 3 of hoger. *Ernstige bijwerkingen (SAE’s). *Bijwerkingen (AE’s) die aanleiding gaven tot dosisaanpassingen (verlaging, onderbreking of overslaan van de dosis of stopzetting van de behandeling). *Afwijkingen in klinische laboratoriumwaarden.","language":18,"languageDescription":"Dutch"},{"id":12576724,"uuid":"bea9ff79-f770-4cec-a400-5a4cbdb2fc8b","attributeTranslation":"4. *Incidence, sévérité et type des événements indésirables apparus sous traitement (EIAT) *Incidence des EIAT de grade ≥ 3. *Événements indésirables graves (EIG). *Événements indésirables (EI) entraînant des modifications de la posologie (réduction, suspension ou interruption de la dose, ou arrêt du traitement). *Anomalies des analyses biologiques.","language":34,"languageDescription":"French (France)"}]},{"id":1176939,"number":5,"endPoint":"5. *Incidence, severity, and type of TEAEs. *Incidence of ≥Grade 3 TEAEs. *SAEs. *AEs leading to dose modifications (dose  reduction, interruption, dose held, or  discontinuation). *Clinical laboratory abnormalities.","isPrimary":false,"endPointTranslations":[{"id":12576729,"uuid":"b1484807-3789-4bdc-befd-750ab99738b6","attributeTranslation":"5. *Częstość występowania, stopień nasilenia i rodzaj TEAE. *Częstość występowania TEAE stopnia ≥3. *SAE. *AE prowadzące do modyfikacji dawki (zmniejszenia dawki, wstrzymania leczenia, odroczenia dawki lub przerwania leczenia). *Nieprawidłowości w badaniach laboratoryjnych.","language":19,"languageDescription":"Polish"},{"id":12576728,"uuid":"b1484807-3789-4bdc-befd-750ab99738b6","attributeTranslation":"5. *Incidence, sévérité et type des EIAT. *Incidence des EIAT de grade ≥ 3. *EIG. *EI entraînant des modifications de la posologie (réduction, suspension ou interruption de la dose, ou arrêt du traitement). *Anomalies des analyses biologiques.","language":34,"languageDescription":"French (France)"},{"id":12576727,"uuid":"b1484807-3789-4bdc-befd-750ab99738b6","attributeTranslation":"5. *Incidentie, ernst en aard van TEAE’s. *Incidentie van TEAE’s van graad 3 of hoger. *SAE's *AE's die aanleiding gaven tot dosisaanpassingen (verlaging, onderbreking of overslaan van de dosis of stopzetting van de behandeling). *Afwijkingen in klinische laboratoriumwaarden.","language":18,"languageDescription":"Dutch"},{"id":12576730,"uuid":"b1484807-3789-4bdc-befd-750ab99738b6","attributeTranslation":"5. * Incidencia, gravedad y tipo de AAST. * Incidencia de AAST de grado ≥3. * AAG. * AA que dan lugar a modificaciones de la dosis (reducción de la dosis, interrupción, retención de la dosis o suspensión). * Anomalías analíticas.","language":7,"languageDescription":"Spanish"}]}]},"trialDuration":{"estimatedGlobalEndDate":"2029-04-30","estimatedEndDate":"2029-04-30","estimatedRecruitmentStartDate":"2026-11-01"},"sourceOfMonetarySupport":[{"id":108798,"organisationName":"Bicara Therapeutics"}],"populationOfTrialSubjects":{"ageRanges":[{"id":405525,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":405524,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[{"id":405526,"ageRangeCategoryCode":"4","ctAgeRangeCode":"7","ageRangeCategory":"4","ctAgeRange":"7"},{"id":405527,"ageRangeCategoryCode":"4","ctAgeRangeCode":"8","ageRangeCategory":"4","ctAgeRange":"8"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"3"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-10-30","conclusionDate":"2026-10-30","therapeuticAreas":[{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}],"medicalConditions":[{"id":154733,"medicalCondition":"Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","isConditionRareDisease":false}],"sponsors":[{"id":168193,"primary":true,"publicContacts":[{"id":496774,"type":"Public","functionalName":"Bicara Therapeutics Inc","functionalEmailAddress":"FORTIFI_Inquiries@bicara.com","telephone":"0016174684219","organisation":{"id":996279,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":496775,"type":"Scientific","functionalName":"Bicara Therapeutics Inc","functionalEmailAddress":"FORTIFI_Inquiries@bicara.com","telephone":"0016174684219","organisation":{"id":996279,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":774182,"organisationAddress":{"id":999047,"organisation":{"id":1042797,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Bioclinica Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100033079","organisationLocationStatus":"Active"},"address":{"addressId":1126185,"oneLine":"1818 Market Street Suite 2600","addressLine1":"1818 Market Street Suite 2600","addressLine2":"","addressLine3":"","addressLine4":"","city":"Philadelphia","postcode":"19103-3600","country":840,"countryName":"United States"},"phone":"+12159720420","email":"BCA101X201@clario.com","isBusinessKeyValidated":true,"businessKey":"LOC-100088223"},"sponsorDuties":[{"id":1198010,"code":"15","value":"Medical imaging"}],"phoneNumber":"+12159720420","email":"BCA101X201@clario.com"},{"id":774183,"organisationAddress":{"id":999033,"organisation":{"id":1042783,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Iqvia Laboratories Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100042527","organisationLocationStatus":"Active"},"address":{"addressId":1126168,"oneLine":"The Alba Campus, Rosebank","addressLine1":"The Alba Campus","addressLine2":"Rosebank","addressLine3":"","addressLine4":"","city":"Livingston","postcode":"EH54 7EG","country":826,"countryName":"United Kingdom"},"phone":"441184501088","email":"q2_eu_clinical_trials_information@q2labsolutions.com","isBusinessKeyValidated":true,"businessKey":"LOC-100087705"},"sponsorDuties":[{"id":1198011,"code":"4"}],"phoneNumber":"441184501088","email":"q2_eu_clinical_trials_information@q2labsolutions.com"},{"id":774181,"organisationAddress":{"id":999034,"organisation":{"id":1042784,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"IQVIA Laboratories LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043195","organisationLocationStatus":"Active"},"address":{"addressId":1126169,"oneLine":"2400 Ellis Road","addressLine1":"2400 Ellis Road","addressLine2":"","addressLine3":"","addressLine4":"","city":"Durham","postcode":"27703-6895","country":840,"countryName":"United States"},"phone":"+441184501088","email":"isabelle.castro@iqvia.com","isBusinessKeyValidated":true,"businessKey":"LOC-100071469"},"sponsorDuties":[{"id":1198009,"code":"4"}],"phoneNumber":"+441184501088","email":"isabelle.castro@iqvia.com"},{"id":774185,"organisationAddress":{"id":881684,"organisation":{"id":923701,"type":"Health care","typeCode":"2","name":"Auxilius, Inc.","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000017162","organisationLocationStatus":"Active"},"address":{"addressId":984308,"oneLine":"249 Smith Street #4020","addressLine1":"249 Smith Street #4020","addressLine2":"","addressLine3":"","addressLine4":"","city":"Brooklyn","postcode":"NY 11231","country":840,"countryName":"United States"},"phone":"12013804453","email":"info@auxili.us","isBusinessKeyValidated":false,"businessKey":"ORL-000017162"},"sponsorDuties":[{"id":1198013,"code":"15","value":"Financial data integration"}],"phoneNumber":"12013804453","email":"info@auxili.us"},{"id":774187,"organisationAddress":{"id":999025,"organisation":{"id":1042774,"type":"Pharmaceutical company","typeCode":"10","name":"Medpace Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100026760","organisationLocationStatus":"Active"},"address":{"addressId":1126159,"oneLine":"5375 Medpace Way","addressLine1":"5375 Medpace Way","addressLine2":"","addressLine3":"","addressLine4":"","city":"Cincinnati","postcode":"45227-1543","country":840,"countryName":"United States"},"phone":"+330788409776","email":"G.Slezak@Medpace.com","isBusinessKeyValidated":true,"businessKey":"LOC-100043279"},"sponsorDuties":[{"id":1198015,"code":"1"},{"id":1198016,"code":"10"},{"id":1198017,"code":"11"},{"id":1198018,"code":"12"},{"id":1198019,"code":"2"},{"id":1198020,"code":"8"},{"id":1198021,"code":"9"}],"phoneNumber":"+330788409776","email":"G.Slezak@Medpace.com"},{"id":774184,"organisationAddress":{"id":999039,"organisation":{"id":1042789,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Revvity Signals Software Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100046158","organisationLocationStatus":"Active"},"address":{"addressId":1126174,"oneLine":"940 Winter Street","addressLine1":"940 Winter Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"Waltham","postcode":"02451-1457","country":840,"countryName":"United States"},"phone":"+7816636900","email":"vijaylakshmi.kulkarni@revvity.com","isBusinessKeyValidated":true,"businessKey":"LOC-100076155"},"sponsorDuties":[{"id":1198012,"code":"15","value":"Data Visualization"}],"phoneNumber":"+7816636900","email":"vijaylakshmi.kulkarni@revvity.com"},{"id":774190,"organisationAddress":{"id":1000837,"organisation":{"id":1044608,"type":"Pharmaceutical company","typeCode":"10","name":"Medpace Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100026760","organisationLocationStatus":"Active"},"address":{"addressId":1128251,"oneLine":"5375 Medpace Way","addressLine1":"5375 Medpace Way","addressLine2":"","addressLine3":"","addressLine4":"","city":"Cincinnati","postcode":"45227-1543","country":840,"countryName":"United States"},"phone":"+15134066907","email":"b.albers@medpace.com","isBusinessKeyValidated":true,"businessKey":"LOC-100043279"},"sponsorDuties":[{"id":1198025,"code":"15","value":"Patient concierge travel reimbursement"}],"phoneNumber":"+15134066907","email":"b.albers@medpace.com"},{"id":774188,"organisationAddress":{"id":999055,"organisation":{"id":1042805,"type":"Non-Pharmaceutical company","typeCode":"11","name":"4g Clinical LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100042775","organisationLocationStatus":"Active"},"address":{"addressId":1126194,"oneLine":"370 Washington Street","addressLine1":"370 Washington Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"Wellesley","postcode":"02481-6207","country":840,"countryName":"United States"},"phone":"+17816941400","email":"info@4gclinical.com","isBusinessKeyValidated":true,"businessKey":"LOC-100070717"},"sponsorDuties":[{"id":1198022,"code":"14"},{"id":1198023,"code":"3"}],"phoneNumber":"+17816941400","email":"info@4gclinical.com"},{"id":774189,"organisationAddress":{"id":999038,"organisation":{"id":1042788,"type":"Pharmaceutical company","typeCode":"10","name":"Iqvia Biotech Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100008726","organisationLocationStatus":"Active"},"address":{"addressId":1126173,"oneLine":"3 Forbury Place, 23 Forbury Road","addressLine1":"3 Forbury Place","addressLine2":"23 Forbury Road","addressLine3":"","addressLine4":"","city":"Reading","postcode":"RG1 3JH","country":826,"countryName":"United Kingdom"},"phone":"+441438310000","email":"Biotech-EUCTR-Support@iqvia.com","isBusinessKeyValidated":true,"businessKey":"LOC-100068833"},"sponsorDuties":[{"id":1198024,"code":"8"}],"phoneNumber":"+441438310000","email":"Biotech-EUCTR-Support@iqvia.com"},{"id":774186,"organisationAddress":{"id":999030,"organisation":{"id":1042780,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Medidata Solutions Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100016256","organisationLocationStatus":"Active"},"address":{"addressId":1126165,"oneLine":"350 Hudson Street","addressLine1":"350 Hudson Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"New York","postcode":"10014-4504","country":840,"countryName":"United States"},"phone":"18666334328","email":"info@medidata.com","isBusinessKeyValidated":true,"businessKey":"LOC-100025034"},"sponsorDuties":[{"id":1198014,"code":"7"}],"phoneNumber":"18666334328","email":"info@medidata.com"}],"organisation":{"id":996279,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"},"addresses":[{"id":952913,"organisation":{"id":996279,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"},"address":{"addressId":1070870,"oneLine":"116 Huntington Avenue Suite 703","addressLine1":"116 Huntington Avenue Suite 703","addressLine2":"","addressLine3":"","addressLine4":"","city":"Boston","postcode":"02116-5784","country":840,"countryName":"United States"},"isBusinessKeyValidated":true,"businessKey":"ORG-100049097"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"BCA101X201 is a Phase 2 which in line with EMA guidance on disclosure rules corresponds to a Category 2 trial.","partOneTherapeuticAreas":[{"id":1267907,"therapeuticArea":{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}}],"productRoleGroupInfos":[{"id":456019,"comments":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","productRoleCode":"1","productRoleName":"Test","products":[{"id":616426,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"14197451","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081132","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"14197451","substancePk":"450549","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136","synonyms":["Lambrolizumab","MK-3475","SCH-900475","BAT3306","Pabolizumab","FYB206","CT P51","SYS6036","QL-2107","CMAB820","ABP 234"]}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"7","productChangedRelationMA":false,"maxTreatmentPeriod":24,"timeUnitCode":"3","otherMedicinalProduct":"humanised monoclonal anti-programmed cell death-1 (PD-1) antibody","evCode":"PRD12081132","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}]},{"id":456018,"comments":"Ficerafusp Alfa","productRoleCode":"1","productRoleName":"Test","products":[{"id":616425,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12980657","productPharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12980657","prodAuthStatus":1,"prodName":"Ficerafusp Alfa","pharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","sponsorProductCode":"BCA101","activeSubstanceName":"FICERAFUSP ALFA","euSubstNumber":"SUB301432","nameOrg":"BICARA","productSubstances":[{"productPk":"12980657","substancePk":"404854","nameOrg":"BICARA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"FICERAFUSP ALFA","substanceEvCode":"SUB301432","synonyms":["Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta","BCA101","Ficerafusp alpha"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2250","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"195.75","maxTreatmentPeriod":60,"timeUnitCode":"3","otherMedicinalProduct":"chimeric EGFR mAb & TGF-β TGF-βRIIECD","evCode":"PRD12980657","sponsorProductCodeEdit":"BCA101","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"Ficerafusp Alfa","jsonActiveSubstanceNames":"ficerafusp alfa","pharmaceuticalFormDisplay":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":345262,"mscId":62293,"mscInfo":{"id":62293,"clinicalTrialId":28674,"countryOrganisationId":2002,"reportingStatusCode":"Authorised","fromDate":"2026-10-05","toDate":"2026-10-05","isProposedRms":true,"expressDecision":"willing","countryName":"Belgium","organisationInfo":{},"firstDecisionDate":"2026-10-30","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":true,"clinicalTrialStatusHistory":[{"id":439733,"mscId":62293,"trialStatus":"Under evaluation","trialStatusDate":"2026-07-10T13:43:20.842"},{"id":525834,"mscId":62293,"trialStatus":"Authorised","trialStatusDate":"2026-10-30T13:47:46.09"}],"applicationTypeMsc":"1","mscName":"Belgium","assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-10-21","decision":"authorized_conditions","decisionDate":"2026-10-30"},"decisionDate":"2026-10-30","recruitmentSubjectCount":6,"trialSites":[{"id":2426775,"organisationAddressInfo":{"id":998854,"organisation":{"id":1042602,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100040731","organisationLocationStatus":"Active"},"address":{"addressId":1125936,"oneLine":"Place Louise Godin 15","addressLine1":"Place Louise Godin 15","addressLine2":"","addressLine3":"","addressLine4":"","city":"Namur","postcode":"5000","country":2002,"countryName":"Belgium"},"phone":"3281720531","email":"stephanie.henry@chuuclnamur.uclouvain.be","isBusinessKeyValidated":true,"businessKey":"LOC-100066979"},"personInfo":{"id":2689627,"firstName":"Stéphanie","lastName":"Henry","telephone":"3281720531","email":"stephanie.henry@chuuclnamur.uclouvain.be","title":"1"},"departmentName":"Oncology"},{"id":2426774,"organisationAddressInfo":{"id":998955,"organisation":{"id":1042704,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Cliniques Universitaires Saint-Luc","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008950","organisationLocationStatus":"Active"},"address":{"addressId":1126062,"oneLine":"Hippokrateslaan 10, Batiment 54","addressLine1":"Hippokrateslaan 10","addressLine2":"Batiment 54","addressLine3":"","addressLine4":"","city":"Sint-Lambrechts-Woluwe","postcode":"1200","country":2002,"countryName":"Belgium"},"phone":"3227645106","email":"jean-pascal.machiels@uclouvain.be","isBusinessKeyValidated":true,"businessKey":"LOC-100014498"},"personInfo":{"id":2689626,"firstName":"Jean-Pascal","lastName":"Machiels","telephone":"3227645106","email":"jean-pascal.machiels@uclouvain.be","title":"2"},"departmentName":"Oncology"},{"id":2426776,"organisationAddressInfo":{"id":998870,"organisation":{"id":1042618,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"AZ Sint-Lucas & Volkskliniek","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041035","organisationLocationStatus":"Active"},"address":{"addressId":1125953,"oneLine":"Groenebriel 1","addressLine1":"Groenebriel 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Gent","postcode":"9000","country":2002,"countryName":"Belgium"},"phone":"3292246620","email":"glen.meert@azslucas.be","isBusinessKeyValidated":true,"businessKey":"LOC-100067562"},"personInfo":{"id":2689628,"firstName":"Glen","lastName":"Meert","telephone":"3292246620","email":"glen.meert@azslucas.be","title":"1"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":337090,"mscId":62294,"mscInfo":{"id":62294,"clinicalTrialId":28674,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2026-09-07","toDate":"2026-09-07","isProposedRms":false,"expressDecision":"unwilling","countryName":"France","organisationInfo":{},"firstDecisionDate":"2026-11-04","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":439734,"mscId":62294,"trialStatus":"Under evaluation","trialStatusDate":"2026-07-10T13:43:20.858"},{"id":526472,"mscId":62294,"trialStatus":"Authorised","trialStatusDate":"2026-11-04T16:38:40.129"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-15","decision":"authorized_conditions","decisionDate":"2026-11-04"},"decisionDate":"2026-11-04","recruitmentSubjectCount":16,"trialSites":[{"id":2369575,"organisationAddressInfo":{"id":997971,"organisation":{"id":1041715,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre De Lutte Contre Le Cancer Eugene Marquis","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029502","organisationLocationStatus":"Active"},"address":{"addressId":1124910,"oneLine":"Avenue La Bataille Flandre Dunkerque, Cs 44229","addressLine1":"Avenue La Bataille Flandre Dunkerque","addressLine2":"Cs 44229","addressLine3":"","addressLine4":"","city":"Rennes Cedex","postcode":"35042","country":2012,"countryName":"France"},"phone":"0299253182","email":"f.estrade@rennes.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"LOC-100046817"},"personInfo":{"id":2626298,"firstName":"Florian","lastName":"Estrade","telephone":"0299253182","email":"f.estrade@rennes.unicancer.fr","title":"1"},"departmentName":"Oncology"},{"id":2369573,"organisationAddressInfo":{"id":997987,"organisation":{"id":1041731,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Henri Becquerel","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029528","organisationLocationStatus":"Active"},"address":{"addressId":1124928,"oneLine":"Rue D Amiens","addressLine1":"Rue D Amiens","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rouen Cedex","postcode":"76038","country":2012,"countryName":"France"},"phone":"0232082981","email":"florian.clatot@chb.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"LOC-100081426"},"personInfo":{"id":2626296,"firstName":"Florian","lastName":"Clatot","telephone":"0232082981","email":"florian.clatot@chb.unicancer.fr","title":"1"},"departmentName":"Oncology"},{"id":2369577,"organisationAddressInfo":{"id":997967,"organisation":{"id":1041711,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Poitiers","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010436","organisationLocationStatus":"Active"},"address":{"addressId":1124906,"oneLine":"2 Rue De La Miletrie","addressLine1":"2 Rue De La Miletrie","addressLine2":"","addressLine3":"","addressLine4":"","city":"Poitiers","postcode":"86000","country":2012,"countryName":"France"},"phone":"0549444279","email":"camille.evrard@chu-poitiers.fr","isBusinessKeyValidated":true,"businessKey":"LOC-100014747"},"personInfo":{"id":2626300,"firstName":"Camille","lastName":"Evrard","telephone":"0549444279","email":"camille.evrard@chu-poitiers.fr","title":"1"},"departmentName":"Oncology"},{"id":2369574,"organisationAddressInfo":{"id":997984,"organisation":{"id":1041728,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire Grenoble Alpes","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007060","organisationLocationStatus":"Active"},"address":{"addressId":1124925,"oneLine":"Boulevard De La Chantourne, Cs 10217, La Tronche","addressLine1":"Boulevard De La Chantourne","addressLine2":"Cs 10217","addressLine3":"La Tronche","addressLine4":"","city":"Grenoble Cedex 9","postcode":"38043","country":2012,"countryName":"France"},"phone":"0476765451","email":"jpavillet@chu-grenoble.fr","isBusinessKeyValidated":true,"businessKey":"LOC-100011284"},"personInfo":{"id":2626297,"firstName":"Julien","lastName":"Pavillet","telephone":"0476765451","email":"jpavillet@chu-grenoble.fr","title":"1"},"departmentName":"Oncology"},{"id":2369572,"organisationAddressInfo":{"id":997958,"organisation":{"id":1041702,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Regional De Marseille","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008698","organisationLocationStatus":"Active"},"address":{"addressId":1124897,"oneLine":"264 Rue Saint Pierre","addressLine1":"264 Rue Saint Pierre","addressLine2":"","addressLine3":"","addressLine4":"","city":"Marseille","postcode":"13005","country":2012,"countryName":"France"},"phone":"0491385708","email":"sebastien.salas@ap-hm.fr","isBusinessKeyValidated":true,"businessKey":"LOC-100073107"},"personInfo":{"id":2626295,"firstName":"Sebastien","lastName":"Salas","telephone":"0491385708","email":"sebastien.salas@ap-hm.fr","title":"2"},"departmentName":"Oncology"},{"id":2369576,"organisationAddressInfo":{"id":997962,"organisation":{"id":1041706,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centr Georges Francois Leclerc","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100011048","organisationLocationStatus":"Active"},"address":{"addressId":1124901,"oneLine":"1 Rue Professeur Marion","addressLine1":"1 Rue Professeur Marion","addressLine2":"","addressLine3":"","addressLine4":"","city":"Dijon","postcode":"21000","country":2012,"countryName":"France"},"phone":"0380737500","email":"hbellio@cgfl.fr","isBusinessKeyValidated":true,"businessKey":"LOC-100015116"},"personInfo":{"id":2626299,"firstName":"Helene","lastName":"Bellio","telephone":"0380737500","email":"hbellio@cgfl.fr","title":"1"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":347651,"mscId":62295,"mscInfo":{"id":62295,"clinicalTrialId":28674,"countryOrganisationId":2013,"reportingStatusCode":"Authorised","fromDate":"2026-10-13","toDate":"2026-10-13","isProposedRms":false,"expressDecision":"unwilling","countryName":"Germany","organisationInfo":{},"firstDecisionDate":"2026-11-03","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":439735,"mscId":62295,"trialStatus":"Under evaluation","trialStatusDate":"2026-07-10T13:43:20.873"},{"id":526236,"mscId":62295,"trialStatus":"Authorised","trialStatusDate":"2026-11-03T07:41:19.177"}],"applicationTypeMsc":"1","mscName":"Germany","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-23","decision":"authorized_conditions","decisionDate":"2026-11-03"},"decisionDate":"2026-11-03","recruitmentSubjectCount":22,"trialSites":[{"id":2445449,"organisationAddressInfo":{"id":1001213,"organisation":{"id":1044991,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Koeln AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100012761","organisationLocationStatus":"Active"},"address":{"addressId":1128693,"oneLine":"Kerpener Strasse 62, Lindenthal","addressLine1":"Kerpener Strasse 62","addressLine2":"Lindenthal","addressLine3":"","addressLine4":"","city":"Cologne","postcode":"50937","country":2013,"countryName":"Germany"},"phone":"+491736562585","email":"malte.suchan@uk-koeln.de","isBusinessKeyValidated":true,"businessKey":"LOC-100030763"},"personInfo":{"id":2710154,"firstName":"Malte","lastName":"Suchan","telephone":"+491736562585","email":"malte.suchan@uk-koeln.de"},"departmentName":"Department of Otorhinolaryngology, Head and Neck Surgery"},{"id":2445454,"organisationAddressInfo":{"id":1000507,"organisation":{"id":1044274,"type":"Educational Institution","typeCode":"1","name":"University Of Luebeck","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100031253","organisationLocationStatus":"Active"},"address":{"addressId":1127873,"oneLine":"Ratzeburger Allee 160, Strecknitz","addressLine1":"Ratzeburger Allee 160","addressLine2":"Strecknitz","addressLine3":"","addressLine4":"","city":"Luebeck","postcode":"23562","country":2013,"countryName":"Germany"},"phone":"+4945150042012","email":"Ursula.Schroeder@uksh.de","isBusinessKeyValidated":true,"businessKey":"LOC-100049039"},"personInfo":{"id":2710159,"firstName":"Ursula","lastName":"Schröder","telephone":"+4945150042012","email":"Ursula.Schroeder@uksh.de","title":"1"},"departmentName":"University clinic Schleswig-Holstein, Campus Lübeck"},{"id":2445457,"organisationAddressInfo":{"id":1000607,"organisation":{"id":1044374,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Heidelberg AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100013733","organisationLocationStatus":"Active"},"address":{"addressId":1127990,"oneLine":"Im Neuenheimer Feld 460, Neuenheim","addressLine1":"Im Neuenheimer Feld 460","addressLine2":"Neuenheim","addressLine3":"","addressLine4":"","city":"Heidelberg","postcode":"69120","country":2013,"countryName":"Germany"},"phone":"+4962215638027","email":"Tilmann.Bochtler@med.uni-heidelberg.de","isBusinessKeyValidated":true,"businessKey":"LOC-100069559"},"personInfo":{"id":2710162,"firstName":"Tilmann","lastName":"Bochtler","telephone":"+4962215638027","email":"Tilmann.Bochtler@med.uni-heidelberg.de","title":"1"},"departmentName":"Heidelberg University Hospital   Department of Medical Oncology"},{"id":2445458,"organisationAddressInfo":{"id":1000656,"organisation":{"id":1044424,"type":"Educational Institution","typeCode":"1","name":"Justus-Liebig-Universitaet Giessen","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100028650","organisationLocationStatus":"Active"},"address":{"addressId":1128045,"oneLine":"Klinikstrasse 33","addressLine1":"Klinikstrasse 33","addressLine2":"","addressLine3":"","addressLine4":"","city":"Giessen","postcode":"35392","country":2013,"countryName":"Germany"},"phone":"+4964198543701","email":"christine.langer@hno.med.uni-giessen.de","isBusinessKeyValidated":true,"businessKey":"LOC-100068883"},"personInfo":{"id":2710163,"firstName":"Christine","lastName":"Langer","telephone":"+4964198543701","email":"christine.langer@hno.med.uni-giessen.de","title":"1"},"departmentName":"Universitaetsklinikum Giessen Klinik für Hals-, Nasen- und Ohrenheilkunde"},{"id":2445456,"organisationAddressInfo":{"id":1000535,"organisation":{"id":1044302,"type":"Educational Institution","typeCode":"1","name":"Heidelberg University","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100030880","organisationLocationStatus":"Active"},"address":{"addressId":1127907,"oneLine":"Theodor-Kutzer-Ufer 1-3, Wohlgelegen","addressLine1":"Theodor-Kutzer-Ufer 1-3","addressLine2":"Wohlgelegen","addressLine3":"","addressLine4":"","city":"Mannheim","postcode":"68167","country":2013,"countryName":"Germany"},"phone":"+496213833965","email":"annette.affolter@umm.de","isBusinessKeyValidated":true,"businessKey":"LOC-100070734"},"personInfo":{"id":2710161,"firstName":"Annette","lastName":"Affolter","telephone":"+496213833965","email":"annette.affolter@umm.de","title":"1"},"departmentName":"Department of Otorhinolaryngology, Head and Neck Surgery,   Experimental Head and Neck Oncology"},{"id":2445452,"organisationAddressInfo":{"id":1000625,"organisation":{"id":1044392,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Asklepios Kliniken Hamburg GmbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100021958","organisationLocationStatus":"Active"},"address":{"addressId":1128009,"oneLine":"Paul-Ehrlich-Strasse 1, Othmarschen","addressLine1":"Paul-Ehrlich-Strasse 1","addressLine2":"Othmarschen","addressLine3":"","addressLine4":"","city":"Hamburg","postcode":"22763","country":2013,"countryName":"Germany"},"phone":"+49401818811211","email":"d.arnold@asklepios.com","isBusinessKeyValidated":true,"businessKey":"LOC-100035052"},"personInfo":{"id":2710157,"firstName":"Dirk","lastName":"Arnold","telephone":"+49401818811211","email":"d.arnold@asklepios.com","title":"1"},"departmentName":"Asklepios Klinik Altona - Onkologie, Hämatologie, Palliativmedizin, Rheumatologie und Pneumologie"},{"id":2445451,"organisationAddressInfo":{"id":1000690,"organisation":{"id":1044458,"type":"Educational Institution","typeCode":"1","name":"Universitaet Leipzig","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100000273","organisationLocationStatus":"Active"},"address":{"addressId":1128089,"oneLine":"Liebigstrasse 12, Zentrum-Suedost","addressLine1":"Liebigstrasse 12","addressLine2":"Zentrum-Suedost","addressLine3":"","addressLine4":"","city":"Leipzig","postcode":"04103","country":2013,"countryName":"Germany"},"phone":"+493419721814","email":"dietz_studien@medizin.uni-leipzig.de","isBusinessKeyValidated":true,"businessKey":"LOC-100066259"},"personInfo":{"id":2710156,"firstName":"Andreas","lastName":"Dietz","telephone":"+493419721814","email":"dietz_studien@medizin.uni-leipzig.de","title":"2"},"departmentName":"Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde"},{"id":2445453,"organisationAddressInfo":{"id":1000689,"organisation":{"id":1044457,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Wuerzburg AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100013011","organisationLocationStatus":"Active"},"address":{"addressId":1128088,"oneLine":"Pleicherwall 2, Altstadt","addressLine1":"Pleicherwall 2","addressLine2":"Altstadt","addressLine3":"","addressLine4":"","city":"Wuerzburg","postcode":"97070","country":2013,"countryName":"Germany"},"phone":"+4993120172720","email":"mueller_u2@ukw.de","isBusinessKeyValidated":true,"businessKey":"LOC-100090560"},"personInfo":{"id":2710158,"firstName":"Urs","lastName":"Müller-Richter","telephone":"+4993120172720","email":"mueller_u2@ukw.de","title":"2"},"departmentName":"Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie des Universitätsklinikums"},{"id":2445448,"organisationAddressInfo":{"id":1000633,"organisation":{"id":1044400,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Schleswig-Holstein AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023619","organisationLocationStatus":"Active"},"address":{"addressId":1128020,"oneLine":"Arnold-Heller-Strasse 3, Brunswik","addressLine1":"Arnold-Heller-Strasse 3","addressLine2":"Brunswik","addressLine3":"","addressLine4":"","city":"Kiel","postcode":"24105","country":2013,"countryName":"Germany"},"phone":"+4943150022555","email":"Anne.Letsch@uksh.de","isBusinessKeyValidated":true,"businessKey":"LOC-100032773"},"personInfo":{"id":2710153,"firstName":"Anne","lastName":"Letsch","telephone":"+4943150022555","email":"Anne.Letsch@uksh.de","title":"1"},"departmentName":"Universitätsklinikum Schleswig Holstein Klinik für Innere Medizin Hämatologie und Onkologie,"},{"id":2445450,"organisationAddressInfo":{"id":1000581,"organisation":{"id":1044348,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"University Medical Center Hamburg-Eppendorf","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008810","organisationLocationStatus":"Active"},"address":{"addressId":1127958,"oneLine":"Martinistrasse 52, Eppendorf","addressLine1":"Martinistrasse 52","addressLine2":"Eppendorf","addressLine3":"","addressLine4":"","city":"Hamburg","postcode":"20246","country":2013,"countryName":"Germany"},"phone":"+4915222816055","email":"schafhausen@uke.de","isBusinessKeyValidated":true,"businessKey":"LOC-100014580"},"personInfo":{"id":2710155,"firstName":"Philippe","lastName":"Schafhausen","telephone":"+4915222816055","email":"schafhausen@uke.de","title":"1"},"departmentName":"Department of oncology,hematology,and bone marrow transplantation with section of pneumology"},{"id":2445455,"organisationAddressInfo":{"id":1000592,"organisation":{"id":1044359,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"LMU Klinikum Muenchen AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008479","organisationLocationStatus":"Active"},"address":{"addressId":1127971,"oneLine":"Marchioninistrasse 15, Hadern","addressLine1":"Marchioninistrasse 15","addressLine2":"Hadern","addressLine3":"","addressLine4":"","city":"Munich","postcode":"81377","country":2013,"countryName":"Germany"},"phone":"+498944000","email":"christoph.reichel@med.uni-muenchen.de","isBusinessKeyValidated":true,"businessKey":"LOC-100012841"},"personInfo":{"id":2710160,"firstName":"Christoph","lastName":"Reichel","telephone":"+498944000","email":"christoph.reichel@med.uni-muenchen.de","title":"1"},"departmentName":"Klinikum der Universität München Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde"}],"applicationStatusCode":"Authorised"},{"id":347509,"mscId":62296,"mscInfo":{"id":62296,"clinicalTrialId":28674,"countryOrganisationId":2018,"reportingStatusCode":"Authorised","fromDate":"2026-10-13","toDate":"2026-10-13","isProposedRms":false,"expressDecision":"unwilling","countryName":"Italy","organisationInfo":{},"firstDecisionDate":"2026-11-03","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":439736,"mscId":62296,"trialStatus":"Under evaluation","trialStatusDate":"2026-07-10T13:43:20.886"},{"id":526323,"mscId":62296,"trialStatus":"Authorised","trialStatusDate":"2026-11-03T15:31:01.647"}],"applicationTypeMsc":"1","mscName":"Italy","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-20","decision":"authorized_conditions","decisionDate":"2026-11-03"},"decisionDate":"2026-11-03","recruitmentSubjectCount":6,"trialSites":[{"id":2444269,"organisationAddressInfo":{"id":1000913,"organisation":{"id":1044685,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"IRCCS Istituto Nazionale Tumori Fondazione Pascale","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010025","organisationLocationStatus":"Active"},"address":{"addressId":1128346,"oneLine":"Via Mariano Semmola 52","addressLine1":"Via Mariano Semmola 52","addressLine2":"","addressLine3":"","addressLine4":"","city":"Naples","postcode":"80131","country":2018,"countryName":"Italy"},"phone":"+393489145086","email":"f.perri@istitutotumori.na.it","isBusinessKeyValidated":true,"businessKey":"LOC-100016007"},"personInfo":{"id":2708894,"firstName":"Francesco","lastName":"Perri","telephone":"+393489145086","email":"f.perri@istitutotumori.na.it","title":"1"},"departmentName":"Oncology"},{"id":2444268,"organisationAddressInfo":{"id":1000940,"organisation":{"id":1044712,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007489","organisationLocationStatus":"Active"},"address":{"addressId":1128375,"oneLine":"Via Piero Maroncelli 40","addressLine1":"Via Piero Maroncelli 40","addressLine2":"","addressLine3":"","addressLine4":"","city":"Meldola","postcode":"47014","country":2018,"countryName":"Italy"},"phone":"0543739100","email":"Sebastiano.calpona@irst.emr.it","isBusinessKeyValidated":true,"businessKey":"LOC-100011622"},"personInfo":{"id":2708893,"firstName":"Sebastiano","lastName":"Calpona","telephone":"0543739100","email":"Sebastiano.calpona@irst.emr.it","title":"1"},"departmentName":"Oncology"},{"id":2444267,"organisationAddressInfo":{"id":1000928,"organisation":{"id":1044700,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Ospedale San Raffaele S.r.l.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006123","organisationLocationStatus":"Active"},"address":{"addressId":1128363,"oneLine":"Via Olgettina 60","addressLine1":"Via Olgettina 60","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20132","country":2018,"countryName":"Italy"},"phone":"0226433526","email":"MIRABILE.AURORA@HSR.IT","isBusinessKeyValidated":true,"businessKey":"LOC-100011477"},"personInfo":{"id":2708892,"firstName":"Aurora","lastName":"Mirabile","telephone":"0226433526","email":"MIRABILE.AURORA@HSR.IT","title":"1"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":338288,"mscId":62297,"mscInfo":{"id":62297,"clinicalTrialId":28674,"countryOrganisationId":2027,"reportingStatusCode":"Authorised","fromDate":"2026-09-10","toDate":"2026-09-10","isProposedRms":false,"expressDecision":"unwilling","countryName":"Spain","organisationInfo":{},"firstDecisionDate":"2026-11-04","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":439737,"mscId":62297,"trialStatus":"Under evaluation","trialStatusDate":"2026-07-10T13:43:20.9"},{"id":526390,"mscId":62297,"trialStatus":"Authorised","trialStatusDate":"2026-11-04T07:41:55.287"}],"applicationTypeMsc":"1","mscName":"Spain","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-05","decision":"authorized_conditions","decisionDate":"2026-11-04"},"decisionDate":"2026-11-04","recruitmentSubjectCount":15,"trialSites":[{"id":2377891,"organisationAddressInfo":{"id":999727,"organisation":{"id":1043482,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Catala D'oncologia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030394","organisationLocationStatus":"Active"},"address":{"addressId":1126963,"oneLine":"Carretera Canyet S/n","addressLine1":"Carretera Canyet S/n","addressLine2":"","addressLine3":"","addressLine4":"","city":"Badalona","postcode":"08916","country":2027,"countryName":"Spain"},"phone":"0034934978925","email":"nbaste@iconcologia.net","isBusinessKeyValidated":true,"businessKey":"LOC-100069414"},"personInfo":{"id":2635556,"firstName":"Neus","lastName":"Baste Rotllan","telephone":"0034934978925","email":"nbaste@iconcologia.net"},"departmentName":"Medical Oncology"},{"id":2377892,"organisationAddressInfo":{"id":999738,"organisation":{"id":1043493,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Clinico San Carlos","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023073","organisationLocationStatus":"Active"},"address":{"addressId":1126974,"oneLine":"Calle Del Profesor Martin Lagos Sn","addressLine1":"Calle Del Profesor Martin Lagos Sn","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28040","country":2027,"countryName":"Spain"},"phone":"+34913303000","email":"santiago.cabezas@salud.madrid.org","isBusinessKeyValidated":true,"businessKey":"LOC-100031822"},"personInfo":{"id":2635557,"firstName":"Santiago","lastName":"Cabezas Camarero","telephone":"+34913303000","email":"santiago.cabezas@salud.madrid.org"},"departmentName":"Medical Oncology"},{"id":2377890,"organisationAddressInfo":{"id":999735,"organisation":{"id":1043490,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Miguel Servet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041170","organisationLocationStatus":"Active"},"address":{"addressId":1126971,"oneLine":"Paseo De Isabel La Catolica 1-3","addressLine1":"Paseo De Isabel La Catolica 1-3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Zaragoza","postcode":"50009","country":2027,"countryName":"Spain"},"phone":"+34976765500","email":"jmtrufero@seom.org","isBusinessKeyValidated":true,"businessKey":"LOC-100067790"},"personInfo":{"id":2635555,"firstName":"Javier","lastName":"Martinez Trufero","telephone":"+34976765500","email":"jmtrufero@seom.org"},"departmentName":"Medical Oncology"},{"id":2377895,"organisationAddressInfo":{"id":999732,"organisation":{"id":1043487,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Y Politecnico La Fe","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029610","organisationLocationStatus":"Active"},"address":{"addressId":1126968,"oneLine":"Avenida Fernando Abril Martorell 106","addressLine1":"Avenida Fernando Abril Martorell 106","addressLine2":"","addressLine3":"","addressLine4":"","city":"Valencia","postcode":"46026","country":2027,"countryName":"Spain"},"phone":"+34961245877","email":"caballero_jav@gva.es","isBusinessKeyValidated":true,"businessKey":"LOC-100051169"},"personInfo":{"id":2635560,"firstName":"Javier","lastName":"Caballero Daroqui","telephone":"+34961245877","email":"caballero_jav@gva.es"},"departmentName":"Medical Oncology"},{"id":2377893,"organisationAddressInfo":{"id":999731,"organisation":{"id":1043486,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fundacion Instituto Valenciano De Oncologia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100032608","organisationLocationStatus":"Active"},"address":{"addressId":1126967,"oneLine":"Calle Professor Beltran Baguena 8","addressLine1":"Calle Professor Beltran Baguena 8","addressLine2":"","addressLine3":"","addressLine4":"","city":"Valencia","postcode":"46009","country":2027,"countryName":"Spain"},"phone":"0034961114000","email":"haguilar@fivo.org","isBusinessKeyValidated":true,"businessKey":"LOC-100069308"},"personInfo":{"id":2635558,"firstName":"Hector Augusto","lastName":"Aguilar Andino","telephone":"0034961114000","email":"haguilar@fivo.org"},"departmentName":"Medical Oncology"},{"id":2377894,"organisationAddressInfo":{"id":999736,"organisation":{"id":1043491,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Fundacion Jimenez Diaz","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028994","organisationLocationStatus":"Active"},"address":{"addressId":1126972,"oneLine":"Avenida De Los Reyes Catolicos 2","addressLine1":"Avenida De Los Reyes Catolicos 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28040","country":2027,"countryName":"Spain"},"phone":"+34915504800","email":"pablo.fpaco@quironsalud.es","isBusinessKeyValidated":true,"businessKey":"LOC-100046216"},"personInfo":{"id":2635559,"firstName":"Pablo","lastName":"Flores Paco","telephone":"+34915504800","email":"pablo.fpaco@quironsalud.es"},"departmentName":"Medical Oncology"},{"id":2377889,"organisationAddressInfo":{"id":999739,"organisation":{"id":1043494,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"University Hospital Virgen Del Rocio S.L.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030783","organisationLocationStatus":"Active"},"address":{"addressId":1126975,"oneLine":"Avenida De Manuel Siurot S/n","addressLine1":"Avenida De Manuel Siurot S/n","addressLine2":"","addressLine3":"","addressLine4":"","city":"Sevilla","postcode":"41013","country":2027,"countryName":"Spain"},"phone":"+34955013368","email":"fatima.toscano.sspa@juntadeandalucia.es","isBusinessKeyValidated":true,"businessKey":"LOC-100048439"},"personInfo":{"id":2635554,"firstName":"Fatima","lastName":"Toscano Murillo","telephone":"+34955013368","email":"fatima.toscano.sspa@juntadeandalucia.es"},"departmentName":"Medical Oncology"}],"applicationStatusCode":"Authorised"},{"id":345595,"mscId":62298,"mscInfo":{"id":62298,"clinicalTrialId":28674,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2026-10-06","toDate":"2026-10-06","isProposedRms":false,"expressDecision":"unwilling","countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2026-11-03","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":526242,"mscId":62298,"trialStatus":"Authorised","trialStatusDate":"2026-11-03T09:47:49.045"},{"id":439738,"mscId":62298,"trialStatus":"Under evaluation","trialStatusDate":"2026-07-10T13:43:20.913"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-26","decision":"authorized_conditions","decisionDate":"2026-11-03"},"decisionDate":"2026-11-03","recruitmentSubjectCount":4,"trialSites":[{"id":2428647,"organisationAddressInfo":{"id":999166,"organisation":{"id":1042916,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Groningen","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022118","organisationLocationStatus":"Active"},"address":{"addressId":1126320,"oneLine":"Hanzeplein 1","addressLine1":"Hanzeplein 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Groningen","postcode":"9713 GZ","country":2029,"countryName":"Netherlands"},"phone":"+31503612370","email":"s.oosting@umcg.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100030831"},"personInfo":{"id":2691710,"firstName":"Sjoukje","lastName":"Oosting","telephone":"+31503612370","email":"s.oosting@umcg.nl"},"departmentName":"Internal Medicine"},{"id":2428648,"organisationAddressInfo":{"id":999173,"organisation":{"id":1042923,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Radboud universitair medisch centrum Stichting","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023234","organisationLocationStatus":"Active"},"address":{"addressId":1126327,"oneLine":"Geert Grooteplein Zuid 10","addressLine1":"Geert Grooteplein Zuid 10","addressLine2":"","addressLine3":"","addressLine4":"","city":"Nijmegen","postcode":"6525 GA","country":2029,"countryName":"Netherlands"},"phone":"+31243610353","email":"Carla.vanHerpen@radboudumc.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100032073"},"personInfo":{"id":2691711,"firstName":"Carla","lastName":"van Herpen","telephone":"+31243610353","email":"Carla.vanHerpen@radboudumc.nl"},"departmentName":"Medical Oncology"}],"applicationStatusCode":"Authorised"},{"id":344229,"mscId":62299,"mscInfo":{"id":62299,"clinicalTrialId":28674,"countryOrganisationId":2031,"reportingStatusCode":"Authorised","fromDate":"2026-09-30","toDate":"2026-09-30","isProposedRms":false,"expressDecision":"unwilling","countryName":"Poland","organisationInfo":{},"firstDecisionDate":"2026-11-02","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":439739,"mscId":62299,"trialStatus":"Under evaluation","trialStatusDate":"2026-07-10T13:43:20.927"},{"id":526215,"mscId":62299,"trialStatus":"Authorised","trialStatusDate":"2026-11-02T20:31:05.064"}],"applicationTypeMsc":"1","mscName":"Poland","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-26","decision":"authorized_conditions","decisionDate":"2026-11-02"},"decisionDate":"2026-11-02","recruitmentSubjectCount":8,"trialSites":[{"id":2419791,"organisationAddressInfo":{"id":999562,"organisation":{"id":1043316,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009191","organisationLocationStatus":"Active"},"address":{"addressId":1126776,"oneLine":"Ul. Wybrzeze Armii Krajowej 15","addressLine1":"Ul. Wybrzeze Armii Krajowej 15","addressLine2":"","addressLine3":"","addressLine4":"","city":"Gliwice","postcode":"44-102","country":2031,"countryName":"Poland"},"phone":"322788345","email":"tomasz.rutkowski@gliwice.nio.gov.pl","isBusinessKeyValidated":true,"businessKey":"LOC-100016102"},"personInfo":{"id":2681857,"firstName":"Tomasz","lastName":"Rutkowski","telephone":"322788345","email":"tomasz.rutkowski@gliwice.nio.gov.pl","title":"2"},"departmentName":"Centrum Wsparcia Badań Klinicznych"},{"id":2419792,"organisationAddressInfo":{"id":999557,"organisation":{"id":1043311,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100043855","organisationLocationStatus":"Active"},"address":{"addressId":1126771,"oneLine":"Ul. Ksiecia Jozefa Poniatowskiego 26","addressLine1":"Ul. Ksiecia Jozefa Poniatowskiego 26","addressLine2":"","addressLine3":"","addressLine4":"","city":"Siedlce","postcode":"08-110","country":2031,"countryName":"Poland"},"phone":"698826497","email":"lbodnar@szpital.siedlce.pl","isBusinessKeyValidated":true,"businessKey":"LOC-100072436"},"personInfo":{"id":2681858,"firstName":"Lubomir","lastName":"Bodnar","telephone":"698826497","email":"lbodnar@szpital.siedlce.pl","title":"2"},"departmentName":"Siedleckie Centrum Onkologii, Oddział Onkologii Klinicznej i Radioterapii"},{"id":2419793,"organisationAddressInfo":{"id":999563,"organisation":{"id":1043317,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009191","organisationLocationStatus":"Active"},"address":{"addressId":1126777,"oneLine":"Ul. Wilhelma Konrada Roentgena 5","addressLine1":"Ul. Wilhelma Konrada Roentgena 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Warsaw","postcode":"02-781","country":2031,"countryName":"Poland"},"phone":"225462214","email":"andrzej.kawecki@nio.gov.pl","isBusinessKeyValidated":true,"businessKey":"LOC-100017986"},"personInfo":{"id":2681859,"firstName":"Andrzej","lastName":"Kawecki","telephone":"225462214","email":"andrzej.kawecki@nio.gov.pl","title":"2"},"departmentName":"Klinika Nowotworów Głowy i Szyi"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":83085,"type":"INITIAL","status":"Authorised","ctNumber":"2026-526741-10-00","trialStatus":"Authorised","submissionDate":"2026-07-10","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-10-30"},"partIIInfo":[{"id":345262,"mscId":62293,"mscInfo":{"id":62293,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-10-21","decision":"authorized_conditions","decisionDate":"2026-10-30","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2026-10-30"},"applicationStatusCode":"Authorised"},{"id":337090,"mscId":62294,"mscInfo":{"id":62294,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-15","decision":"authorized_conditions","decisionDate":"2026-11-04","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2026-11-04"},"applicationStatusCode":"Authorised"},{"id":347651,"mscId":62295,"mscInfo":{"id":62295,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-23","decision":"authorized_conditions","decisionDate":"2026-11-03","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2026-11-03"},"applicationStatusCode":"Authorised"},{"id":347509,"mscId":62296,"mscInfo":{"id":62296,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-20","decision":"authorized_conditions","decisionDate":"2026-11-03","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2026-11-03"},"applicationStatusCode":"Authorised"},{"id":338288,"mscId":62297,"mscInfo":{"id":62297,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-05","decision":"authorized_conditions","decisionDate":"2026-11-04","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2026-11-04"},"applicationStatusCode":"Authorised"},{"id":345595,"mscId":62298,"mscInfo":{"id":62298,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-26","decision":"authorized_conditions","decisionDate":"2026-11-03","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2026-11-03"},"applicationStatusCode":"Authorised"},{"id":344229,"mscId":62299,"mscInfo":{"id":62299,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-26","decision":"authorized_conditions","decisionDate":"2026-11-02","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2026-11-02"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-10-30","ctMSCsByApplication":[{"id":62293,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":62294,"mscName":"France","reportingStatusCode":"Authorised"},{"id":62295,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":62296,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":62297,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":62298,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":62299,"mscName":"Poland","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":149156,"applicationId":83085,"mscId":62298,"mscName":"Netherlands","decisionDate":"2026-11-03T09:47:50.828","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":345595,"part1Id":147374,"applicationType":"INITIAL","isRMS":false},{"id":149332,"applicationId":83085,"mscId":62297,"mscName":"Spain","decisionDate":"2026-11-04T07:41:56.331","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":338288,"part1Id":147374,"applicationType":"INITIAL","isRMS":false},{"id":149473,"applicationId":83085,"mscId":62294,"mscName":"France","decisionDate":"2026-11-04T16:38:41.325","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":337090,"part1Id":147374,"applicationType":"INITIAL","isRMS":false},{"id":149257,"applicationId":83085,"mscId":62296,"mscName":"Italy","decisionDate":"2026-11-03T15:31:03.018","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":347509,"part1Id":147374,"applicationType":"INITIAL","isRMS":false},{"id":148826,"applicationId":83085,"mscId":62293,"mscName":"Belgium","decisionDate":"2026-10-30T13:47:47.556","decision":"authorized_conditions","assessmentOutcome":"acceptable_conditions","eventType":"decision","part2Id":345262,"part1Id":147374,"applicationType":"INITIAL","isRMS":true},{"id":149127,"applicationId":83085,"mscId":62299,"mscName":"Poland","decisionDate":"2026-11-02T20:31:06.076","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":344229,"part1Id":147374,"applicationType":"INITIAL","isRMS":false},{"id":149142,"applicationId":83085,"mscId":62295,"mscName":"Germany","decisionDate":"2026-11-03T07:41:20.2","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":347651,"part1Id":147374,"applicationType":"INITIAL","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"c9e2dcf7-d2f8-4467-b902-1ddd1b6a0b0a","productRoleGroupId":456019}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Netherlands","mscId":62298,"firstDecisionDate":"2026-11-03T09:47:50.828","lastDecisionDate":"2026-11-03T09:47:50.828","mscPublicStatusCode":2},{"mscName":"Spain","mscId":62297,"firstDecisionDate":"2026-11-04T07:41:56.331","lastDecisionDate":"2026-11-04T07:41:56.331","mscPublicStatusCode":2},{"mscName":"France","mscId":62294,"firstDecisionDate":"2026-11-04T16:38:41.325","lastDecisionDate":"2026-11-04T16:38:41.325","mscPublicStatusCode":2},{"mscName":"Italy","mscId":62296,"firstDecisionDate":"2026-11-03T15:31:03.018","lastDecisionDate":"2026-11-03T15:31:03.018","mscPublicStatusCode":2},{"mscName":"Belgium","mscId":62293,"firstDecisionDate":"2026-10-30T13:47:47.556","lastDecisionDate":"2026-10-30T13:47:47.556","mscPublicStatusCode":2},{"mscName":"Poland","mscId":62299,"firstDecisionDate":"2026-11-02T20:31:06.076","lastDecisionDate":"2026-11-02T20:31:06.076","mscPublicStatusCode":2},{"mscName":"Germany","mscId":62295,"firstDecisionDate":"2026-11-03T07:41:20.2","lastDecisionDate":"2026-11-03T07:41:20.2","mscPublicStatusCode":2}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":62293,"mscName":"Belgium","events":[]},{"mscId":62294,"mscName":"France","events":[]},{"mscId":62295,"mscName":"Germany","events":[]},{"mscId":62296,"mscName":"Italy","events":[]},{"mscId":62297,"mscName":"Spain","events":[]},{"mscId":62298,"mscName":"Netherlands","events":[]},{"mscId":62299,"mscName":"Poland","events":[]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Protocol_2026-526741-10_Bicara_redacted","uuid":"5d4a3c30-cca5-4ffc-a5fc-2ee2006bba51","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Technical protocol synopsis_EN_2026-526741-10_Bicara_redacted","uuid":"4f02cb5e-1d07-454a-bd8c-f83b51f24e87","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Technical protocol synopsis_FR_2026-526741-10_Bicara_redacted","uuid":"a4f5629e-1c1b-44b7-9d92-320d268738b0","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Lay protocol synopsis_EN_2026-526741-10_Bicara_redacted","uuid":"db814018-b2de-4214-934c-2db946ab83a7","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Lay protocol synopsis_ES_2026-526741-10_Bicara_redacted","uuid":"9d6032aa-438a-4a52-86ff-57dcbf680a9d","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Lay protocol synopsis_IT_2026-526741-10_Bicara_redacted","uuid":"0f681c5b-9927-4af9-b172-03da95b6aaee","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Lay protocol synopsis_FR_2026-526741-10_Bicara_redacted","uuid":"69d83d03-738f-4dba-9d10-e8a89a033d64","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Lay protocol synopsis_DU_2026-526741-10_Bicara_redacted","uuid":"bedad2d9-c0ec-40cd-bd77-9152056f2870","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":18,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Lay protocol synopsis_DE_2026-526741-10_Bicara_redacted","uuid":"b4250715-a7e6-446c-b754-b7622c3368c0","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"D1_Lay protocol synopsis_PL_2026-526741-10_Bicara_redacted","uuid":"4c25ffbd-b716-40a0-9073-c4be9a28664b","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":147374,"manualVersion":"1.2","systemVersion":"2"},{"title":"E2_SmPC_Pembrolizumab_Bicara","uuid":"c9e2dcf7-d2f8-4467-b902-1ddd1b6a0b0a","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":456019,"manualVersion":"NA","systemVersion":"1"},{"title":"K1_Recruitment arrangements_BE_Bicara","uuid":"2e7d1129-afb4-42af-8152-854c99daefea","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Brochure_DU_Bicara_redacted","uuid":"7619d64a-b557-4f77-8599-1f5729a35abd","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1","systemVersion":"2"},{"title":"K2_Recruitment material_Brochure_EN_Bicara_redacted","uuid":"2bc2e79a-700c-4bfa-9b9d-5ea40ee0684e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1","systemVersion":"2"},{"title":"K2_Recruitment material_Brochure_FR_Bicara_redacted","uuid":"dc84e0d2-1d98-4252-b392-721792d6ad21","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1","systemVersion":"2"},{"title":"L1_SIS and ICF_Main_DU_Bicara_redacted","uuid":"e64724b3-1b70-4b9f-a2e6-b1e94b6cba8e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Main_EN_Bicara_redacted","uuid":"77a433cd-8165-4cb1-9de1-f0aa99c6adea","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Main_FR_Bicara_redacted","uuid":"d4dc60c3-7578-489a-8a23-dda61b88385d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnancy_DU_Bicara_redacted","uuid":"090a01a4-0b1f-454d-bd38-08be96f7fbac","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnancy_EN_Bicara_redacted","uuid":"351c4f32-05dc-41d0-9691-79ef839f3be6","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnancy_FR_Bicara_redacted","uuid":"9a69dadc-ffbe-4873-8649-a13d7a0e042c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":345262,"manualVersion":"1.0","systemVersion":"2"},{"title":"K1_Recruitment arrangements_FR_Bicara","uuid":"9a9c2c11-191b-4273-9f43-881b0ffb3866","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":337090,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Brochure_Bicara_redacted","uuid":"e0f5371b-8d23-4e8a-8e59-e9b8596867ed","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":337090,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_Main ICF_Bicara_redacted","uuid":"1028f229-2b57-462f-a5c4-6963bc4fb790","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":337090,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnant Partner - Participant ICF_Bicara_redacted","uuid":"0878eecb-080d-404d-a3e9-0332cd0f81f0","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":337090,"manualVersion":"1.0","systemVersion":"1"},{"title":"K1_Recruitment arrangements_DE_Bicara","uuid":"ea557b5a-6837-42e6-8227-d4c581828ab0","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":347651,"manualVersion":"1.0","systemVersion":"2"},{"title":"K2_Recruitment material_Brochure_Bicara_redacted","uuid":"4400b099-1579-4df4-918e-034287c11ca3","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":347651,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_Main ICF_Bicara_redacted","uuid":"96d978f1-673c-4ae7-8677-c0b5fabe9ccd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":347651,"manualVersion":"1.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Future Research ICF_Bicara_redacted","uuid":"4326272e-fed6-4353-a451-a8844a867b0c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":347651,"manualVersion":"1.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Pregnant Partner ICF_Bicara_redacted","uuid":"feee5b02-f1db-4ac1-98ab-c4e7527e3d6f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":347651,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnant Participant ICF_Bicara_redacted","uuid":"cb04a684-cf00-4259-8edb-a96887c28b58","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":347651,"manualVersion":"1.0","systemVersion":"1"},{"title":"K1_Recruitment arrangements_IT_Bicara","uuid":"eae409bd-6500-445c-9348-f00a79909035","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":347509,"manualVersion":"1","systemVersion":"1"},{"title":"K2_Recruitment material_Brochure_Bicara_redacted","uuid":"7d5ae1c0-e051-4a63-8904-f8e8d39308b0","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":347509,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Bicara_redacted","uuid":"7afdd05b-4f35-4fa3-a74a-7c83431795d1","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":347509,"manualVersion":"1.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Data Privacy_Bicara_redacted","uuid":"65094f01-f4e8-4cdf-b0c2-1e9f3c5cf6ca","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":347509,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnancy_Bicara_redacted","uuid":"cd116d43-6f1c-48bd-bd3a-81c3eee92165","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":347509,"manualVersion":"1.0","systemVersion":"3"},{"title":"K1_Recruitment arrangements_ES_Bicara","uuid":"098c2cba-887b-4579-b268-eee4db7c7472","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338288,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Brochure_Bicara_redacted","uuid":"455b795a-cbb3-4748-aa21-7a5e891ce3fa","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":338288,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Bicara_redacted","uuid":"a7dbd90a-411f-427b-8792-af6bc6365414","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":338288,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnant Partner_Bicara_redacted","uuid":"fced641f-8366-48c5-a424-12821ba8a2db","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":338288,"manualVersion":"1.0","systemVersion":"1"},{"title":"K1_Recruitment arrangements_NL_Bicara","uuid":"a72c0871-89f9-4618-9aca-a5271bb00b27","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":345595,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Brochure_Bicara_redacted","uuid":"22d52826-5d44-4778-b09b-c53c054465db","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":345595,"manualVersion":"1","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnancy_Bicara_redacted","uuid":"f2e8aa23-f3d8-495b-94fa-59ff77b06966","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":345595,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Bicara_redacted","uuid":"4744ee44-2963-4b64-85aa-dc3aab2b694d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":345595,"manualVersion":"1.0","systemVersion":"2"},{"title":"K1_Recruitment arrangements_PL_Bicara","uuid":"5a1b744e-c7c1-471b-a622-5fa03236efcd","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":344229,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Brochure_Bicara_redacted","uuid":"a9c04c67-3000-4ad5-84f0-bdfc2c2ab340","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":344229,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Bicara_redacted","uuid":"db0cc7c8-0027-4696-a306-2c991b852c58","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":344229,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnant Partner_redacted","uuid":"f8d9e68e-f3dc-4220-b1ac-050e0b3588b0","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":344229,"manualVersion":"1.0","systemVersion":"2"}],"trialRegion":"Both","trialRegionCode":3,"correctiveMeasures":[]}